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Introduction
Increasing life expectancy will inevitably lead to a raise in the incidence of
neurodegenerative diseases, such as Alzheimer’s disease (AD), Huntington’s dis-
ease (HD) and Parkinson’s disease (PD), with a social impact that can not be
trascured. In particular, PD aﬀects 1 in 500 of the general population and 1 in
100 of those individuals aged 60 or over: it is considered the second most common
neurodegenerative disease after AD.
Beside several studies to investigate the aetiology and the pathogenesis of this
illness, new potential treatments are being tested, in order to overcome the prob-
lematics showed by the traditional ones. In fact, current therapies for PD can be
reasonably described as highly eﬀective and at the same time inadequate: sub-
stantial, even if partial, improvements in the motor deﬁcits of PD are reliably
produced by standard therapies, which are primarily designed to boost dopamin-
ergic signaling in the striatum. Usually, to increase the production of endogenous
dopamine, its precursor, L-DOPA, is used but, even if all the dopaminergic ther-
apies are eﬀective in the initial stages of the illness, they become inadequate as
the disease progresses, do not reverse non-motor symptomatology and become as-
sociated with adverse eﬀects that are diﬃcult to manage. In particular, the most
irreversible adverse eﬀect of chronic dopaminergic therapy is the development of
involuntary jerking or writhing movements known as dyskinesias.
This latter shortfall of dopaminergic therapy has prompted a search for new
nondopaminergic modulators of basal ganglia motor circuits that may provide
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alternative or adjunctive treatment with a reduced side-eﬀect proﬁle. The basal
ganglia is in fact involved in motor control and sensorimotor integration, and
recent studies have demonstrated how dopamine and adenosine interact to mod-
ulate motor function at this level. In this background, the antagonists of the A2A
subtype of adenosine receptors have emerged as a leading candidate class of non-
dopaminergic antiparkinsonian agents, based primarily on their functional eﬀects
of improving motor deﬁcits in rodent and primate models of PD, as well as sev-
eral preliminary clinical studies. In particular, their relatively restricted pattern
of expression within the Striatum area likely contributes to the low side-eﬀect
proﬁle observed thus far in PD patients and the results suggest that they can be
used as a monotherapy or togheter with L-DOPA, interacting positively with this
type of drug.
In our work, we have analyzed a dataset oﬀered by the Imperial College of Lon-
don: it is composed of six subjects (3 dyskinetic Parkinson’s disease subjects, 2
Parkinson’s disease subjects and 1 healthy control) who were scanned on a PET
camera after the injection of a new tracer, [11C]SCH442416. It is an antagonist
of A2A receptors whose kinetics in rodents and monkeys suggest its potential use
for in vivo imaging of this subtype of receptors and, considered in its unlabelled
form and so as a drug, it possible use as a new treatment for PD.
We performed the Positron Emission Tomography quantiﬁcation at region of in-
terest (ROI) level: the advantages are the good signal to noise ratio of the time
activity curves and the existence of well-estabilished techniques for the estimation
of the unknown parameters. One major drawback of this approach is the loss of
resolution of the original PET image.
The aims of this work are manifold: ﬁrst, the study of the main characteristics of
this tracer, in order to compare the evaluations in human subjects with the ones
found with ex vivo and in vivo experiments in rats and in monkeys (our set of
data is relative to the ﬁrst experiment in unhealthy subjects). The second, prin-
cipal and main important objective is the estimation of the most parsimonious
compartmental model to describe the kinetics of the tracer within the brain: we
know that a compartment represents a space or volume in which the tracer is
distributed, while rate constants link compartments and represent the various5
rates of intercompartmental tracer exchange. The validity of a compartmental
approach rests on the validity of some assumptions that may involve tracer ad-
ministration, pharmacologic and metabolic properties of the radiotracer, or the
heterogeneity/homogeneity of tissue.
To ﬁnd the best compartmental structure we ﬁrst resort to an input-output tech-
nique, which is usually referred to in PET literature as Spectral Analysis: it is able
to identify the kinetic components of the tissue tracer activity without speciﬁc
model assumptions. Starting from the result of this I/O model we deﬁned some
compartmental models, and through their comparison and evaluation we proposed
one of them as the best structure to describe the activity of [11C]SCH442416.
Finally, we tried to indagate the characteristics of the proposed compartmental
model, in particular in order to ﬁnd any possible correlations between the sub-
jects, even if the reduced number of patients involved in the study impedes to
apply the main methods of the statistical analysis. In this way the comparison is
reduced to a simple observation of the diﬀerent micro/macroparameters for each
subject.Chapter 2
The Adenosynergic System
Adenosine is present in all tissues of a mammalian organism where it modulates
a variety of important physiological processes, in particular they involve an in-
hibitory tone of neurotransmission and neuroprotective actions in pathological
conditions. The understanding of adenosine production and release in the brain
is therefore of fundamental importance and has been extensively studied.
In this chapter, main events underlying adenosine biosynthesis as well as its im-
portant receptors are presented and discussed.
2.1 Main Characteristics of Adenosine
Adenosine is an endogenous purine nucleoside, composed of a molecule of adenine
attached to a ribose sugar molecule.
Figure 2.1: Adenosine: chemical structure
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Over the past 25 years a general consensus has been reached on the crucial
role of adenosine in the Central Nervous System (CNS) as a modulator of neu-
rotransmission and a neuroprotective agent against neuronal injury. Moreover
it has also been proposed to be a potent regulator of cerebral blood ﬂow: so
adenosine is mainly considered as a neuromodulator which is able to control the
release of some neurotransmitters and to regulate many important biochemical
processes [1]. In particular it is the major regulator of striatal functions, acting
as an intrinsic signal since it is locally produced as a result of the activity of
striatal circuits. Intracellularly, adenosine may be formed from degradation of
adenosine monophosphate (AMP), and then may exit via bi-directional nucle-
oside transporters, whereas there seem to be two main sources for extracellu-
lar concentration. First, when there is an increasing workload of the circuit, a
greater consumption of adenosine triphosphate (ATP) in neurons and astrocytes
is required to maintain membrane potential. Dephosphorylation of ATP (present
intracellularly in the millimolar range) generates adenosine, which levels increase
substantially over basal intracellular levels: this build-up of intracellular adeno-
sine is translated into increased levels of extracellular. This mechanism ensures
that there is a local ﬂuctuation of extracellular adenosine levels as a function
of local activity in the striatum. There is also a second process which increases
the concentration: it is connected to the degradation and metabolism of adenine
nucleotides distributed in the extracellular space [2]. However, irrespective of
its source, under physiological conditions extracellular adenosine concentration
remains very low (nanomolar range) whereas traumatic or hypoxic events and
increased neurotransmitter release lead to a several augmentation of adenosine
levels.
Besides its more general involvement in cellular metabolism, speciﬁc actions of
adenosine in the CNS as neuroeﬀector are believed to be mediated through some
receptors, which have diﬀerent characteristics and aﬃnities for adenosine as we
can see in the next paragraph.2.2. ADENOSINE RECEPTORS 9
2.2 Adenosine Receptors
The action of adenosine is mediated by speciﬁc receptors located on cell mem-
branes, which belong to the family of G protein-coupled receptors, each with 7
transmembrane domains. Currently, four adenosine receptors have been cloned
and characterized: A1, A2A, A2B and A3. Each is encoded by a separate
gene and has diﬀerent functions, although with some overlapping, they have a
widespread distribution all over the body and their recruitment is profoundly
dependent on the speciﬁc pathophysiological situation, which can modulate the
extracellular nucleoside concentrations ([3],[4]).
Figure 2.2: Adenosine receptor’s structure
The adenosine A1 receptor is activeted by nanomolar adenosine concentra-
tions, this process of activation inhibits adenylyl cyclase (a lyase enzyme) and,
as a consequence, the formation of cyclic adenosine monophosphate (cAMP, a
second important messenger) [5].
This subtype is present on neurons and glial cells, both pre and postsynaptically:
the highest expression has been found in the cortex, cerebellum, thalamus and
hippocampus. Moreover it is also present in basal ganglia structures especially in
striatum and here these receptors are present on dopaminergic and glutamater-
gic terminals, colocalized with dopamine D1 receptors. A1 receptors have been
reported to mediate the protective eﬀects of adenosine in preconditioning and
during ischemia or during reperfusion injury in the brain (even if we have to10 2. THE ADENOSYNERGIC SYSTEM
notice they are found in the entire body).
The adenosine A2B receptor has long remained the least known subtype, it
is sure it is expressed at low levels in all tissues and it has a low aﬃnity for
the natural ligand. This subtype activates adenylyl cyclase and so increase the
cAMP: it is the less spread in brain areas.
The adenosine A3 receptor behaves in a similar way to the A1 subtype, al-
though it needs much higher adenosine concentrations to be activated; it inhibits
adenylyl cyclase and so the formation of cAMP. In appearent contrast with its
low aﬃnity for the endogenous ligand, this receptor seems to contribute to the
defense mechanism during ischemic episode, together with A1 receptors. A3 sub-
type is mainly present at intermediate levels in cerebellum and hippocampus
areas. Finally it has been suggested that low-aﬃnity receptors (A3 and A2B) may
be activeted only under pathological conditions, when adenosine concentrations
are markedly increased [5].
The most important subtype is adenosine A2A receptor, which is a glycoprotein
containing a single carbohydrate chain and has a molecular mass of 45 kDa: like
the A1 receptor, it binds adenosine with high aﬃnity. This adenosine receptor
makes an activation of adenylyl cyclase, leading to intracellular cAMP increase
and resulting in stimulation of neuronal activity; this eﬀect is mediated by a Gs
type protein in the periphery, in platelets, neutrophils and lymphocytes whereas
by a Golf subtype in the CNS. In contrast to the widespread distribution of
the other subtypes, A2A receptors are more selectively distributed in the brain,
being abundantly expressed in striatum, globus pallidus, nucleus accumbens and
tuberculum olfactorium; moreover they are present not only on neurons but also
on the vessel walls where they mediate vasodilatation, on blood platelets, on other
blood corpuscolar elements and on glial cells ([4],[6]).
Regarding to our research, this adenosine receptor plays the main important role,
since the tracer of our interesting is speciﬁcally for this subtype. So in the next
sections we will see better the distribution and the interaction of A2A with other
neurotransmitters.
In ﬁgure 2.3 it’s represented the mechanism of coupling of adenosine to its
receptors and its consequences.2.3. A2A RECEPTORS AND BASAL GANGLIA 11
Figure 2.3: Adenosine receptor coupling
2.3 A2A Receptors and Basal Ganglia
The basal ganglia are a richly interconnected neural network involved in adap-
tive control of behavior through interactions with sensorimotor, motivational and
cognitive brain areas: the striatum, which is composed of putamen and caudate
nucleus, is the major input structure of the basal ganglia. The other structures
that compose the basal ganglia are globus pallidus, subthalamic nucleus and sub-
stantia nigra [2].
Ninety percent of striatal neurons are medium-size spiny neurons, named for their
high density of dendritic spines. These are the population of GABAergic striatal
eﬀerent neurons, which are equally divided into two groups: GABAergic enkepha-
linergic (striatopallidal) and GABAergic dynorphinergic (striatonigral) neurons.
They give rise to two striatal eﬀerent pathways, which connect the striatum with
the output structure, called ”direct” and ”indirect” pathways. In the ﬁrst case,
GABAergic dynorphinergic neurons directly connect the striatum with the sub-
stantia nigra pars reticulata (SNr) and the internal segment of the globus pallidus
(GPi). The indirect pathway instead consists of GABAergic enkephalinergic neu-
rons, which connect the striatum with the external segment of the globus pallidus
(GPe), which in turn project to the subthalamic nucleus (STN) and then this
connects to the output structures. Because of these diﬀerences in connectivity,12 2. THE ADENOSYNERGIC SYSTEM
stimulation of the direct pathway results in motor activation and stimulation of
the indirect pathway produces motor inhibition.
As we said before A2A receptor expression is considerably enriched in the stria-
tum and also within the striatum in the population of GABAergic enkephaliner-
gic neurons, and so involved in the indirect pathway, together with D2 dopamine
receptors, both pre and postsinaptically (instead, the other subpopulation of neu-
rons contains adenosine A1 and dopamine D1 receptors). Moreover the A2A re-
ceptor is enriched in all dopamine rich areas of the brain. The discovery of the
colocalization of D2 and A2A receptors has provided the demonstration of the
functional antagonism between adenosine and dopamine in the basal ganglia,
probably because they are both coupled with adenylyl cyclase, but with opposite
eﬀects. So under physiological conditions, activation of A2A receptors is respon-
sible of the increase of cAMP, on which dopamine can exert its inhibitory action:
the activation of the adenosine receptor induces hypolocomotion, while the oppo-
site is observed after D2 stimulation. The study of adenosine/dopamine interac-
tion has provided the molecular and biochemical basis to postulate the possible
therapeutic use of A2A receptors antagonists in Parkinson’s disease (PD).
About Parkinson’s disease it is known that is age related and this remains
the only clearly estabilished predisposing factor. It is characterized by akinesia,
rigidity, tremor and postural abnormalities, but increasingly there is awareness
that it is a much broader illness that induces also non-motor symptoms such as
falling, speech diﬃculties and neuropsychiatric components like depression, anxi-
ety and cognitive decline [7]. Many of these features can precede the onset of motor
symptoms and they are being investigated as early diagnostic features of PD. The
motor symptoms of PD are due primarily to the degeneration of the dopaminer-
gic nigrostriatal pathway, in fact there is the progressive damage of dopaminergic
neurons in the substantia nigra, even if the pathology is widespread, with cell
loss also occurring in many other brain areas. Unluckly the clinical symptoms
appear after approximately 60% of the dopaminergic neurons are damaged and
the dopamine concentration in the striatum drops by about 80%: for this reason
new tecnologies and methods to early recognize this illness are of great interest
and are being developed in these last years. The current therapy for PD is based2.4. A2A ANTAGONISTS AND PARKINSON’S DISEASE 13
on dopaminergic replacement using L-DOPA and dopamine agonists, these lead
to almost complete reversal of motor symptoms in the early stages of the dis-
ease, even if the dopamine agonists do not possess a great eﬃcacy. Moreover with
the disease’s progression and chronic drug treatments the dopaminergic drugs
show a shortening of duration of eﬀect and a signiﬁcant part of patients develop
involuntary movements of dyskinesia, particularly when treated with L-DOPA.
Finally, the major limitations of the current pharmacological treatment of PD is
represented by its substantial ineﬀectiveness in counteracting the degeneration
of dopaminergic neurons. In this regard, it has recently been emphasized that
the blockade of adenosine A2A receptors may potentially represent a valuable
approach in counteracting neuronal death in PD, as explained below.
2.4 A2A Antagonists and Parkinson’s Disease
To understand how this adenosine antagonist can be useful in treatment of PD,
it is better to start from the analysis of the normal condition.
As we said before, the basal ganglia are thought to mediate the learning and
processing of motor acts through the balance of the direct (striatonigral) and the
indirect (striatopallidal) pathways. In the normal state, dopamine facilitates mo-
tor activity both by exciting D1 receptor expressing neurons in the direct pathway
and by inhibiting D2 receptor expressing neurons in the indirect pathway. Adeno-
sine excites neurons in the indirect pathway via adenosine A2A receptors in the
striatum and globus pallidus pars externa (GPe): there are evidences that activa-
tion of these receptors decreases the aﬃnity of D2 for dopamine. So the inhibitory
inﬂuence of the striatonigral direct pathway on output, composed of substantia
nigra pars reticulata and globus pallidus pars interna (SNr/GPi complex), is coun-
terbalanced by the disinhibitory inﬂuence of the striatopallidal indirect pathway
to this complex (Figure 2.4 - left side).
In PD, dopamine deﬁciency causes reduced activation of the dopamine recep-
tors, which results in reduced inhibition of neurons of the indirect pathway and
decreased excitation of the direct pathway neurons: striatopallidal neurons, loos-
ing the inhibitory eﬀect of dopamine while undergoing the stimulatory inﬂuence14 2. THE ADENOSYNERGIC SYSTEM
of adenosine, become hyperactive, while striatonigral ones become hypoactive.
Such imbalanced activity leads to a markedly increased inhibitory output from
SNr/GPi complex to thalamocortical neurons, which produces reduced move-
ments of PD (Figure 2.4 - middle part).
Many authors have suggested that the positive eﬀects of A2A antagonists in
PD rely on the blockade of this subtype of receptors on striatopallidal neurons,
which should dampen their excessive activity and restore some balance between
the two pathways, consequently relieving thalamocortical activity ([6],[7])(Figure
2.4 - rigth side). However the reduced activity in the direct pathway would not
be normalized by blocking sdenosine A2A receptors and so the motor deﬁcits in
PD may be only partially reversed by these antagonists alone. Signiﬁcantly, the
use of A2A antagonists can occur with no risk of the development or expression
of dyskinesia.
Figure 2.4: Schematic representation of adenosine A2A receptor antagonist activity
in Parkinson’s disease. Abbreviations: Dyn, dynorphin; Enk, enkephalin; GPe,
globus pallidus pars externa; GPi, globus pallidus pars interna; SNC, substantia
nigra pars compacta; SNr, substantia nigra pars reticulata; STN, subthalamic
nucleus [6]
Moreover A2A blockade may contribute to counteract tremor and attenuate2.4. A2A ANTAGONISTS AND PARKINSON’S DISEASE 15
dopaminergic cells’ degeneration (neuroprotection) through a mechanism that
may involve the receptors located presinaptically or on glial cells.
Finally, data obtained from several preclinical studies indicate the existence of
beneﬁcial eﬀects of chronic A2A antagonists on patients with PD who have also
developed dyskinetic complications after a long L-DOPA therapy. So they can
be used alone or in combination with dopaminergic drugs. However, although
the neuroprotective and neuroexcitatory eﬀetcs of adenosine A2A antagonists on
parkinsonian neuronal demise appear to be most promising, it should be noted
that (i) activation of A2A receptors produce vasodilation (ii) by acting on A2A re-
ceptors on inﬂammatory cells, adenosine produces anti-inﬂammatory responses,
and (iii) by acting on A2A receptors on endothelial cells, adenosine decreases
endothelial permeability. Therefore, blockade of A2A receptors may produce ad-
verse eﬀects in regions other than the brain, such as the heart, kidney, lung and
inﬂammatory responses in general [6].Chapter 3
Positron Emission Tomography
In the last decades, the evolution of medicine has demanded new ways of imaging
which can improve the knowledge on tissues and body’s organs in comparison with
the simple morfological observations. In this chapter, we will focus our attention
on the characterists and principles of an important imaging technique, called
Positron Emission Tomography (PET), which is moving from the research domain
to clinical applications for oncology, neurology and cardiology.
3.1 Basic Principles of PET Imaging
Positron Emission Tomography is a nuclear imaging modality that excels in de-
picting the biology of living tissue and that enables regional function to be assayed
in a fully quantitative and noninvasive manner. While the resolution of magnetic
resonance imaging (MRI) for structural tissue changes is unsurpassed, the ability
of structural MRI to demonstrate alterations in the physiology and metabolic
function of tissues remains poor. For this reason, combining the functional PET
data with with the high-resolution anatomical maps produced by MRI provides
powerful data sets which allow corrispondences to be identiﬁed and analyze in a
better way the diﬀerent structures [8]. This combination of techniques is recom-
manded especially for the brain, as in our study, since it is a complex neuronal
network in which all subunits can communicate directly or indirectly with each
other.
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This nuclear technique involves the introduction, usually via an intravenous
injection, of a radioactive tracer into the human body: a tracer is essentially a
biological compound of interest labelled with a positron-emitting isotope,where a
positron is a particle with the same mass and charge of an electron, but opposite
sign (it’s the electron’s antiparticle). The isotopes usually used are 11C, 18F, and
15O, because they have relatively short half-lives (minutes to less than two hours),
allowing the tracers to reach equilibrium in the body, but without exposing the
subjects to prolonged periods of radiation.
They are prepared in a cyclotron that accelerates a beam of protons and directs
it towards the target nuclei, thereby incorporating an extra proton into them:
this generates new compounds that are energetically unstable. The isotopes are
then coupled to the compound of interest and that is the tracer. Since they are
unstable, the isotopes undergo a process of decay whereby the excess proton is
converted into a neutron, a positron, and a neutrino: the emitted positron travels
up to a range of a few millimetres in tissue before annihilates with an electron
[9](Figure 3.1 a). This mutual annihilation process produces two 511 keV γ rays
going in opposite directions (they are released at 180 ) and which are detected
by the several rings of PET scanner. This consists of circumferential arrays of
detectors which look for coincidence events, in witch two γ ray interaction occur
almost simultaneously on opposite side of the head (Figure 3.1 b).
Finally, through reconstruction software the tomographic image is obtained: the
count density in the resulting images, assuming appropriate data corrections are
applied, reﬂects the concentration of the positron-emitting isotope in the tissue.
The main characteristics that make PET a charming technique in the neu-
roimaging ﬁeld are superior sensitivity, high quantity of information and a greater
ﬂexibility of incorporating positron labels into biomolecules. On the other side,
the main disadvantage of PET is greater expense in comparison with other tech-
niques.3.1. BASIC PRINCIPLES OF PET IMAGING 19
(a) Positron emission and annihilation
(b) Schematic representation of detectors in PET
Figure 3.1: The main principles of PET imaging20 3. POSITRON EMISSION TOMOGRAPHY
3.2 PET tracers
As we said before, a tracer is an indicator molecule that follows a systemic sub-
stance that might be involved in ﬂow, metabolism or drug-binding processes. The
tracer properties should be analogous to the systemic substance and it should be
introduced into the system in small amounts and not perturb it. Actually diﬀerent
kinds of tracers exist and are chosen to illustrate the particular brain functions
the investigators are interested in: for example [18F]FDG is commonly used to
study the glucose metabolism and [15O]H2O to stimate cerebral blood ﬂow [11].
All the positron-emissing isotopes used are characterized by short half lives (Ta-
ble 3.2) and this is ideal for medical imaging purposes. In fact, if the half life is
too short there is not suﬃcient time to label the compound of interest and get the
dose to the patient before it decays away; on the other side, if the half life is too
longer many of the positrons are emitted after the patient has left the scanner.
However the short half life of positron emitter limits the PET technology to cen-
ters with an on-site cyclotron unit and a nuclear chemistry laboratory: also for
these reasons, it is mainly considered an expensive technique and often limited
to the research area.
Isotope Half-Life (min)
Carbon-11 20.4
Nitrogen-13 9.96
Oxygen-15 2.07
Fluorine-18 109.8
Table 3.1: Common positron-emitting isotopes used
A lot of studies are undergoing in order to develop new tracers with charac-
teristics suitable for molecular imaging of particular metabolic, biochemical or
physiological functions. In particular some speciﬁc tracers, like [11C]SCH442416
and [18F]DOPA, are being studied to evaluate diﬀerent receptor systems: in vivo
receptorial studies with a PET tracer allow for example to calculate parame-
ters like distribution volume or binding potential and to assess the penetration3.3. PET AND [11C]SCH442416 21
through the blood brain barrier (BBB).
However radioligands suitable for PET studies should fulﬁll several criteria, in
particular the properties of an ideal tracer include
receptor aﬃnity in the nanomolar range (high aﬃnity);
high selectivity for the studied process;
permeability across BBB;
high speciﬁc uptake in target tissue;
low nonspeciﬁc binding.
All these characteristics ([10]) are being investigated in vitro e in vivo also
in [11C]SCH442416, which is a new radioligand used in this research work, as we
will see in the next chapters.
The analysis of PET images obtained with one of these tracers can be qualita-
tive, through visive ispection, or quantitative, in this case a mathematical model
or a speciﬁc method are required. Tracer kinetic models in PET provide the math-
ematical framework to calculate the concentration of reactants and products, and
the rate of a biological process, based upon the time course of tracer distribution
in a series of images and the blood concentration of tracer.
Among these, compartmental models are the most common used in PET area, as
we will largely discuss along this thesis.
3.3 PET and [11C]SCH442416
After describing the general principles and functions of positron emission tomog-
raphy, in the next sections we will focus on the characteristics of this new potent
radioligand, which seems to be the ﬁrst tracer suitable for in vivo imaging of
adenosine A2A receptor, giving also some information about the state of art.
3.3.1 Structure and biological proﬁle of [
11C]SCH442416
As explained in Chapter 2, the adenosine A2A receptor subtype is selectively
expressed in some brain’s areas, in particular the high level is reached in the22 3. POSITRON EMISSION TOMOGRAPHY
striatum, where it is functionally linked to dopamine D2 receptors. Experimental
evidence indicates that in striato-pallidal neurons the administration of adenosine
A2A receptor agonists decreases the aﬃnity of dopamine for D2 receptors. These
ﬁndings suggest that adenosine A2A receptor antagonists may be useful in the
treatment of Parkinson’s disease and so in the last years an increasing number of
antagonists for this subtype has been evaluated and developed.
To better understand it is important to underline the diﬀerence between an ago-
nist and an antagonist in pharmacology. An agonist is a substance that binds to
a speciﬁc receptor of a cell and mimics the response of the natural endogenous
ligand: there is the activation of the receptor. Also the antagonist binds to a spe-
ciﬁc receptor but does not active it and does not provoke a biological response,
it has aﬃnity but no eﬃcacy on the receptor and it blocks the binding of the
corrispondent agonist or natural ligand: so there is the inhibition of the receptor.
Several xanthine derivatives with antagonist activity for A2A receptors have been
labeled with positron-emitting isotopes, for example [11C]CSC is highly selective,
but its aﬃnity for this subtype is relatively low, instead [11C]KF17837 has higher
aﬃnity for but a low striatum-to-cerebellum ratio was found when tested in vivo
with PET. Among the [11C]-labeled xanthine ligands the most suitable ligand for
PET application appears to be [11C]KF18446, which shows good in vivo selectiv-
ity and speciﬁcity for the target tissues. Neverthless, the above compounds are
xanthine derivatives and are subject to photoisomerization, which is a speciﬁc
drawback of this class of molecules [10].
To avoid these problems, recently some novel non-xanthine compounds with an-
tagonistic properties toward the adenosine A2A receptor subtype have been syn-
thesized. Among them, the most important compound is SCH442416 used in its
[11C] radiolabelled form (molecular formula C20H19N7O2, Figure 3.2).
Biodistribution studies indicate that all over the body [11C]SCH442416 preferen-
tially accumulates not only in adrenal glands and kidneys, where A2Areceptors
are highly expressed, but also in lung and liver, instead tracer accumulation is
lower in the heart, where adenosine receptors are mainly represented by the A1
subtype. Concerning the brain, which is the organ of interest for our work, the
results clearly show that this tracer permeates the BBB and accumulates in some3.3. PET AND [11C]SCH442416 23
brain’s areas, in agreement with the known regional distribution of adenosine
receptors [10].
Figure 3.2: [11C]SCH442416: chemical structure
3.3.2 In vitro and in vivo evaluation of [
11C]SCH442416
In the ﬁrst receptor-binding study by Todde and coworkers on human cells and
tissues [10], the aﬃnity of this tracer for A2A receptors expressed by the parameter
Ki was 0.048 nM, >10.000 for A2B and A3 and 905 nM for A1: so this tracer
showed a good selectivity and high aﬃnity for the target receptor subtype. The
next step was the evaluation in vivo, ﬁrst on rodents ([12]): in addition to conﬁrm
the results previously reported, these tests found that in all areas the time of
maximum uptake was reached 5 min after the injection, moreover [11C]SCH442416
mainly accumulated in the striatum (Figure 3.3 a), whereas in the remaining brain
regions examined the tracer distribution was lower and homogeneous (this is in
accordance with the localization of A2A receptors). It displayed a good striatum
to cerebellum radioactivity concentration ratio and this reached the maximum
value (4.6±0.27) 15 min after the injection. Analysis of plasma extracts showed
the presence of three main radioactive compounds, one more lipophilic and two
hydrophilic compounds, probably attributable to metabolites; the metabolism of24 3. POSITRON EMISSION TOMOGRAPHY
[11C]SCH442416 revealed to be slow and the plasma concentration of the injected
tracer accounted for more than 40% of total plasma activity after 60 min.
Moresco and coworkers [12] in one of their studies on rats decided also to inject
an intrastriatal dose of quinolinic acid (QA), that it is known produces a selective
destruction of striatal neurons, included GABA enkephalinergic neurons which
express A2A receptor subtype. So the QA induced a reduction of striatal A2A
receptors (Figure 3.3 b) and in particular two weeks after the operation they
observed a 50% decrease in striatum to cerebellum radioactivity concentration
ratio, in comparison with control rats.
(a) Transaxial image: high binding in striatum area (b) Coronal image from an uni-
laterally quinolinic acid (QA)-
treated rat(arrow=injected side)
Figure 3.3: Autoradiography of brain sections obtained at the level of the basal
ganglia after an intravenous injection of [11C]SCH442416 in rats.
This group also performed a study on monkeys and the results were similar: as
previously, they found a rapid brain uptake, in particular reaching in striatum the
maximum value between 2-4 min after the injection and then declined.Striatum
to cerebellum ratio increased with time, reaching a maximum value of 2.2 at
about 15 min (as observed in rats); this value was only slightly reduced during
the following minutes. Also in monkeys, the radioactive compounds present in the
plasma extracts were the same previously observed in rats and also in this case
the metabolism was slow([12],[13]). However, the PET experiment on monkey’s
brain indicated the presence of a high fraction of non speciﬁc binding, in fact3.3. PET AND [11C]SCH442416 25
it was noted the striatum to cerebellum ratios were two times lower than those
measured in rats. We have to underline that in all these studies they used the
cerebellum as a reference region because in this area the number of A2A receptors
is negligible and they found low values of tracer uptake.
In Figure 3.4 we report as an example the tipical curves of concentration of some
regions of interest, which are related to the experiment made by Moresco et al.
on rats and monkeys.
In conclusion, the regional distribution in brain and also in periphery, the
good signal to noise ratio, the low presence of radioactive metabolites and the
good striatum to cerebellum ratios(even if values are a bit low) suggest that
[11C]SCH442416 is applicable as the ﬁrst nonxanthine, highly selective ligand
suitable for the in vivo imaging of adenosine A2A receptors using PET.
Data used in this work regard the ﬁrst in vivo quantiﬁcation of A2A receptors
in human subjects with Parkinson’s disease: recently, Brooks and his coworkers
also have used this tracer, in healthy subjects, but their aim was to demonstrate
the eﬃcacy of a new drug, vipadenant, as a potential treatment of Parkinson’s
disease [14]. They found the binding of this tracer was blocked after some oral
administrations of vipadenant (which binds to the same receptor subtype); they
also proposed a kinetic model and calculated some important parameters, as
distribution volume. Finally, speciﬁc [11C]SCH442416 binding to the cerebellum
brought them to preclude its use as a reference region, in disagreement with
precedent results on animals.26 3. POSITRON EMISSION TOMOGRAPHY
(a) Rats
(b) Monkeys
Figure 3.4: Tipical time course of regional radioactivity concentration present in
literature. % ID/g represents the percentage of injected dose per gram of tissue.Chapter 4
[
11C]SCH442416: Subjects and
Sperimental Data
In this chapter we present the data used for the quantitative analysis, the protocol
and the subjects.
4.1 Protocol and Subjects
PET experiments were performed at Hammersmith Imanet, London, using ECAT
EXACT HR+ (Siemens/CTI, Knoxville, TN): this scanner consists of four rings,
each made up of 72 block detectors. The ring diameter is 82.7 cm and the axial
ﬁeld of view (FOV) is 15.5 cm; the entire brain can be imaged simultaneously
with a spatial resolution of 4-5 mm.
The number of slices acquired by this tomograph was 63, and for each slice the
protocol expected 34 frames of diﬀerent length, in particular it respected the
following time grid: 1 x 30 sec, 6 x 10 sec, 3 x 20 sec, 3 x 30 sec, 4 x 1 min, 6
x 2 mins, 8 x 5 mins, 3 x 10 mins, for a total of 90 mins. Moreover all subjects
underwent a T1 weighted MRI of the brain, useful to have information about the
region of interest (ROI) placement and to examine the structure of the brain.
This study involved six patients, each with a particular clinical history: in table
4.1 we report the diagnosis for each subject and the dose of radioactivity injected
for the analysis, even if for one subject we do not have the last information.
2728 4. [11C]SCH442416: SUBJECTS AND SPERIMENTAL DATA
Number Subject Diagnosis Injected dose(MBq)
1 1814 Parkinson’s disease with Dyskinesia 656.28
2 1711 Parkinson’s disease -
3 2241 Parkinson’s disease with Dyskinesia 588
4 1804 Parkinson’s disease 485.45
5 1866 Parkinson’s disease with Dyskinesia 656.99
6 2300 Healthy 635
Table 4.1: Subjects involved in the study. Dyskinesia involves uncontrolled and
unusual movements of the body, it often spreads after a long treatment with
L-DOPA drug.
4.2 [11C]SCH442416 Data
4.2.1 [
11C]SCH442416 Blood Sample Analysis
Arterial blood sampling was initiated concurrently with the start of the tracer
infusion and samples were automatically collected during all the experiment us-
ing a ﬂow-through monitoring system that measures the radioactivity, so we have
about 5400 samples for each subject. Also the total plasma (i.e without red cells)
radioactivity concentration is measured.
Additionally, other 9 (or 8 in same cases) blood samples were collected at spe-
ciﬁc time points throughout the study and used to determine the fraction of
unmetabolized [11C]SCH442416 (of total plasma radioactivity concentration) us-
ing high-performance liquid chromatography HPLC. Plasma data were corrected
for the presence of radiolabeled metabolites of the tracer using the HPLC data:
the parent plasma concentration was obtained. So for each subject we have, be-
sides the fraction of radioactive metabolites, the radioactivity concentration in
total blood Cb(t), in total plasma Ctp(t) and in parent plasma Cp(t).
In Figure 4.1 we report for each subject the time course of parent compound
measured in plasma, i.e the fraction of unmetabolized tracer. From the obser-
vation of the curves, it is clear the diﬀerence with results already present in4.2. [11C]SCH442416 DATA 29
literature, in fact while during previous evaluation in vivo on animals, a low
metabolism and a big amount of unmetabolized tracer even at the end of the
experiments were found, here we can observe a rapid decrease and after 7 mins,
on average, the fraction of unmetabolized [11C]SCH442416 in plasma decreases
by approximately 50%.
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Figure 4.1: Parent compound
All blood signals were ﬁrst corrected for the presence of delay, which is due
to a comprehensive diﬀerence between the tracer arrival in the brain and the
arterial sampling site and can greatly inﬂuence the goodness of estimates if not
taken into account. In Table 4.2 we report the delay values stimated for the
subjects: for subject 2300 (control), since we did not have the precise value, we
applied to the arterial input function some diﬀerent values (from 7 to 15 secs)
and, ﬁtting the time-activity curve of some regions of interest with a simple
two-tissue compartmental model, we selected the delay time that minimized the
Akaike Information Criterion (AIC).30 4. [11C]SCH442416: SUBJECTS AND SPERIMENTAL DATA
Subject Delay (sec)
1814 7
1711 13
2241 15
1804 14
1866 7
2300 7
Table 4.2: Delay values for the 6 subjects
Moreover, all blood misures were corrected for the decay, using the formula
A0 = At × e
λt (4.1)
where At and A0 are respectively the uncorrected and corrected value of con-
centration at time t, which is expressed in minute, λ =
ln2
T1/2
with T1/2 half-life
of the radioactive isotope (in our case 20.4 mins).
4.2.2 PET data
PET data were corrected for attenuation and scatter; 43 Regions of interest
(ROIs) were drawn and applied to the dynamic PET data to generate time activ-
ity curves. The following ROIs were considered: Hippocampus, Amygdala, Ante-
rior Temporal Lobe-medial part, Anterior Temporal Lobe-lateral part, Parahip-
pocampal and Ambient Gyri, Superior Temporal Gyrus, Middle and Inferior Tem-
poral Gyrus, Occipital Temporal Gyrus, Cerebellum, Brainstem, Insula, Occip-
ital Lobe, Anterior Cingulate Gyrus, Posterior Cingulate Gyrus, Frontal Lobe,
Posterior Temporal Lobe, Parietal Lobe, Caudate nucleus, Nucleus accumbens,
Putamen, Thalamus, Pallidum.
Each region, expect Brainstem, is separately considered in its left and right part.
In our work, we applied the diﬀerent models and methods to all ROIs, but the
most relevant ones are the regions closely connected with the distribution of
adenosine A2A receptors, i.e Caudate Nucleus, Putamen, Nucleus Accumbens,
Pallidum where this subtype is particulary aboundant and Cerebellum, Thala-4.2. [11C]SCH442416 DATA 31
mus, Anterior Cingulate Gyrus where the distribution of receptors is negligible.
To undestand where these areas are collocated in the human brain, we report in
Figure 4.2 some T1 weigthed MRI slices, relative to subject 1711.
(a) Transaxial view-Slice 83
(b) Sagittal view-Slice 128
Figure 4.2: Diﬀerent slices from subject 1711 showing the position within the brain
of the most important areas for our work32 4. [11C]SCH442416: SUBJECTS AND SPERIMENTAL DATA
For each subject, PET image was transfered to Matlab and we obtained a 4D
matrix, 128x128x63x34 where 63 is the number of slices and 34 the number of
frames of diﬀerent length. We made a ﬁrst qualitative analysis, in order to see
the distribution of tracer in the brain, so after summing multiple time frames, we
made a mask to limite the noise in the images obtaining in this way new summed
PET images. Usually the sum of ﬁrst minutes is made, because it better reﬂects
the arrival and distribution of tracer, but in our case, after trying diﬀerent com-
binations of sum, we did not ﬁnd signiﬁcant diﬀerences in the resulting summed
PET images and so we decided to consider the sum from 0 to 90 mins after the
tracer injection. From the observation of summed PET images, it is clear that
there is a rapid uptake of [11C]SCH442416 in the brain, following the known re-
gional distribution of A2A receptors, in particular, as we can see in Figure 4.3,
tracer rapidly accumulates in Striatum - Globus Pallidus whereas in the other
regions the accumulation of radioactivity is signiﬁcantly lower. So the internal
structures show higher activity than cortical brain areas.
Finally, the decay correction, as before explained for the blood misures, was
applied to the data relative to each region of interest, generating the tissue-time
activity curves (TACs): in Figure 4.4-6 for the 6 subjects we represent in the left
column the total blood curve (Cb(t)) and the parent plasma curve (Cp(t)), which
are corrected for delay and decay, instead in the right column there are some
decay corrected TACs of the regions of our interesting.4.2. [11C]SCH442416 DATA 33
(a) High tracer uptake in the Striatum area and Globus Pallidus
(b) Particular of Cerebellum area, where the uptake is very low
Figure 4.3: In these ﬁgure we represent some summed PET images coregistered to
their relative MRI for subject 1711, in order to display the diﬀerent tracer uptake34 4. [11C]SCH442416: SUBJECTS AND SPERIMENTAL DATA
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Figure 4.4: Control Subject. Left column: blood and unmetabolized plasma ac-
tivity curves. Right column: tissue-time activity curves for 4 regions of interest,
after averaging the left and right part.
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Figure 4.5: Subjects with Parkinson’s disease. Left column: blood and unmetab-
olized plasma activity curves. Right column: tissue-time activity curves for 4
regions of interest, after averaging the left and right part.4.2. [11C]SCH442416 DATA 35
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Figure 4.6: Subjects with Parkinson’s disease and Dyskinesia. Left column: blood
and unmetabolized plasma activity curves. Right column: tissue-time activity
curves for 4 regions of interest, after averaging the left and right part.Chapter 5
Models and Methods
This chapter is dedicated to all ROI models used to analyze [11C]SCH442416:
models are divided into input/output models (Spectral Analysis), which principles
and potentialities are described in the ﬁrst part and models with arterial input
function (Compartmental Models).
5.1 I/O Models: Spectral Analysis
5.1.1 Deﬁnition of Spectral Analysis
The most widely used I/O model in PET studies is the so called Spectral Analysis
(SA), a technique that was introduced by Cunningham and Jones in 1993 in order
to determinate local metabolic rate of glucose in the brain, but now is commonly
used with various PET tracers to study physiological systems other than brain
e.g. liver, heart, kidneys, etc ...[15]. It is a method for analysis of dynamic PET
data that allows identiﬁcation of kinetic components of the tissue tracer activity
without prior assumptions, e.g about tissue equilibration, product loss and the
presence or absence of homogeneity in the tissues.
SA is based on the fact that if a system is linear, the impulse response can be
written as
h(t) =
M  
j=1
αj   e
−βjt (5.1)
and the radioactivity in the tissue at time t, Ctiss(t), is modelled as a convolution
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of the plasma concentration Cp(t) with a sum of M exponential terms:
Ctiss(t) = Cp(t) ⊗ h(t) =
M  
j=1
Cp(t) ⊗ αj   e
−βjt (5.2)
This can be rewritten as:
Ctiss(t) =
M  
j=1
αj  
  t
0
Cp(τ)e
−βj(t−τ)dτ (5.3)
where αj and βj parameters are assumed to be positive or zero. This constrain
derives from an assumption of ﬁrst order tracer kinetics. The upper limit M rep-
resents the maximum number of terms to be included in the model and this is
set to a large number, usually 100. The values of βj are predetermined and ﬁxed
in order to cover an appropriate spectral range, so that the model is linear in
αj. For in vivo studies involving short lived positron emitting isotopes this range
needs to extend to the slowest possible event of the tracer in the tissue up to a
value appropriate to transient phenomena (e.g. the passage of activity through
the tissue vasculature).
In general the corresponding term for βj → ∞ (i.e. βj with a very large value)
is proportional to Cp(t) and can be seen as a “high-frequency component”. In
the same way the corresponding term with a βj → 0 is proportional to
 
Cp and
can be considered as a “low-frequency” component, i.e accounting for irreversible
trapping of the tracer. Finally, the components corresponding to the intermedi-
ate values βj, “intermediate frequency”, reﬂect the extravascular activity of the
tracer [16]. This late number is very important because it gives an idea of tissue
heterogeneity. Moreover, if the analysis is performed at ROI level, as in our work,
the contribute of the vascular component can not be disregarded (as at pixel
level) and so there is the introduction in the previous formula of a term, Vb (that
has to be estimated together with alfa values) accounting for blood volume and
which is proportional to the blood activity curve Cb(t).
Starting from these features, is very common to deﬁne SA model equation explic-
itly showing the trapping in the following way:
Ctiss(t) = α0  
  t
0
Cp(τ)dτ +
M  
j=2
αj  
  t
0
Cp(τ)e
−βj(t−τ)dτ + VbCb(t) (5.4)
with β1 = 0.5.1. I/O MODELS: SPECTRAL ANALYSIS 39
The ﬁrst step to implement the SA model is to deﬁne a grid of βj values:
diﬀerent distributions can be used but, since in our work this procedure has
required diﬀerent tests, we will describe in detail the choice of these exponents in
the next section.
Fixed the M beta values, the M+1 unknown values of the kinetic components (αjs
and Vb) are estimated via non-negative linear weighted least squares algorithms.
In our work this operation has been done using the lsqnonneg function included
in Matlab, which requires the deﬁnition of
vector W, size Nx1 with N number of time points, it contains the chosen
weights (in our case they are the inverse of variance);
matrix C, size Nx(M+1), which has in the ﬁrst M columns the value of the
convolution of the input function with the exponential term, while in the
last one it has the total blood concentration. All these values are multiplied
for the square root of weights;
vector d, size Nx1, which contains the weighted values of tissue activity,
measured at N time points;
vector x, size (M+1)x1, with the unknown elements αj and Vb.
This function minimizes the weighted sum of squares of the residuals and re-
turns an optimal vector of parameters which are ≥ 0. The result of the estimation
is called “spectrum”: it is important to note that, even if there is a large number
of coeﬃcients to be estimated, at most N of them can be nonzero, so there are
few positive peaks in the spectrum.
The interpretation of the spectrum and its components are discussed in Section
5.1.3.
5.1.2 Selection of the Set of Exponents: Beta Grid
The selection of the best set of exponents βj as input in spectral analysis consists
of choosing an upper and a lower bound for the values of βj, as well as a distri-
bution of these coeﬃcients within the chosen interval. Several distributions are40 5. MODELS AND METHODS
used, including linear, quadratic, logarithmic ones, but usually the traditional SA
grid follows the DiStefano distribution, which was used for the ﬁrst time in SA
with [18F]FDG PET data [16].
This is the ﬁrst beta grid that we tested for our SA approach. The lower limit of
this distribution is deﬁned as β1 = (1/3Tend) where Tend represents the length of
the experiment (in our case 90 mins). The upper limit is given by βM = (3/Tin)
where Tin is the value of the ﬁrst scan (in our case 30 sec). Within this interval,
the values are distributed in the following way:
βj =
1
τj
(5.5)
where
τj = τj−1  
 
Tend
Tin
  1
M−1
(5.6)
with j = 2,3,..., M-1.
We chose M = 100 and added at the beginning of the grid β0 = 0.
For the second beta grid we followed a linear distribution of the exponents:
using PET data relative to subject 1814, we started with a ﬁxed grid from 0 to 1.6
min−1 linearly divided into a large number of values, M = 3200. After applying
SA with this grid to all ROIs of the examined subjects, the representation of all
beta values connected to positive alfa coeﬃcients showed two peaks corresponding
respectively to the ﬁrst and the last values of the ﬁxed grid, instead, within the
interval, a normal distribution could be observed.
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Figure 5.1: Distribution of β values for all the ROIs of subject 18145.1. I/O MODELS: SPECTRAL ANALYSIS 41
So we described this Gaussian function with its mean and standard deviation
and using these information we created a new grid linearly equispaced in 100
values from mean-3std to mean+3std, adding then at the beginning and at the
end the values of 0 and 1.6 (which is a suﬃcient high value). We used this last
grid for all the 6 subjects even if it was set starting from the data of the ﬁrst
subject.
Lastly, a third beta grid was tested, starting from the analysis of the results
obtained with the previous grid approach we decided to thicken the linear grid in
its ﬁrst part, in order to better characterize the subjects with slow kinetics.
So this last grid ranges from 0 to 0.00945 with spacing of 0.00005, from 0.0095
to 1.1778 with spacing of 0.0118 and in the last position there is as previous the
value 1.6.
In Table 5.1 we report the main characteristics of each examined beta grid, in
particular we report the SA approaches implemented with each speciﬁc grid. In
fact, before choosing the best one, we tested each grid on diﬀerent SA techiques.
In Figure 5.2 we show the diﬀerent distribution of betas with the three ﬁxed
grid; we have to underline that the formula suggested by DiStefano was modiﬁed
in the value of the exponent, in order to obtain an increasing distribution with
β1 < β2 <     < βM.42 5. MODELS AND METHODS
Grid First value Last value Step Number M of components Methods
First Beta Grid 0 6 Variable (Equations 5.5-6) 101 Traditional SA
Second Beta Grid 0 1.6 0.0118 102 Traditional SA
SAIF
Third Beta Grid 0 1.6 from 0 to 0.00945:0.00005 291 Traditional SA
from 0.0095 to 1.6: 0.0118 SAIF
SA with double input
Table 5.1: For each grid, we report the minimum and maximum value, the step
between two adjacent components and the methods tested with the grid under
consideration. At the end, we choose to use for all the diﬀerent approaches the
third beta grid
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5.1.3 The Features of Spectral Analysis
The estimation of αj and βj from data provides useful insight into the system
behavior and their interpretation can led to the deﬁnition of the best compart-
mental model: spectral analysis and compartmental model approach are strong
correlated each other.
As we said before, a distinction is made between low, intermediate and high
βj components (frequency components). The amplitude αj corresponding to the
highest βj value (βj → ∞) gives a measure of the vasculature within the ROI; the
estimated α value in the last position (M+1) represents the blood volume term
Vb. The amplitude αj corresponding to the lowest βj value (βj = 0 or → 0) reveals
the trapping of the tracer and suggests the presence of an irreversible compart-
ment in the related model. Finally, the number of nonzero αj corrisponding to
the intermediate βj values is connected to the number of identiﬁcable reversible
compartments within the ROI exchanging with plasma. So in SA each component
refers at least to one compartment; the problem is that the spectrum can not say
how the compartments are linked each other, for example discrimination of two
reversible tissue compartments does not estabilish if they are parallel (hetero-
geneous tissues) or catenary (homogenous tissues). Therefore it is impossible to
determine an unequivocal correspondence between the spectrum and model, this
tecnique can only suggest a set of possible compartmental representations which
has the same number and type of components.
Components detected with SA can also be combined in order to obtain pa-
rameters of physiological interest. For example Cunningham et al.([15],[17]) used
the resulting α and β components to estimate the unidirectional clearance of
tracer from blood to tissue, K1, and the volume of distribution of the tracer in
the tissue,Vd, determined as:
K1 = h(t = 0) =
M  
j=0
αj (5.7)
Vd =
  ∞
0
h(t)dt =
M  
j=1
αj
βj
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Instead, if the α0 component corrisponding to β = 0 is detected (the coeﬃcient
of the integral of the plasma concentration), it represents the uptake rate constant,
K, i.e the unidirectional trapping of the tracer:
K = α0 (5.9)
Sometimes results of SA are used to obtain kinetic parameters and rate constants
but in this case a speciﬁc compartmental system structure is required to interprete
them.
This tecnique has many positive elements, ﬁrst of all the fact that it does not
require to ﬁx the number of components necessary to characterise the data, but
rather it provides an estimate of the minimum number of compartments useful to
describe the kinetics of the system. Furthermore the SA does not require steady
state conditions for the tracer, as the graphical analysis technique and it provides
a very good ﬁt of data, this because only the data, without any prior assumptions,
are used to provide the spectrum and so the ﬁnal results are in perfect correlation
with them. This last characteristic has on the other side a negative consequence:
SA ﬁts the data so well that it tracks also the noise and so the results can be
corrupted by the presence of noise, with changes in the shape of the spectrum. In
fact noise in the data usually shifts the components from their true positions and
sometimes can produce non-realistic components called “phantom components”,
both at high and low frequencies. About the accuracy, the SA technique has
lower precision in parameter estimates than the compartmental model approach,
this is due to the large number of parameters of the SA model equation (100 or
more) and it is also conditioned by the ﬁxed grid. Moreover there is usually the
problem of “double components”, due to the discrete nature of the beta grid: the
SA can not place all the components in their correct positions, but only at betas
deﬁned by the grid. As a consequence, sometimes the algorithm splits the real
kinetic components in two adjacent parts and so the corresponding α values are
estimated with low precision.
Lastly we can say that the SA tecnique has a good eﬃciency and, even if for the
non-negativity constrain on α values it is possible to use only algorithms that
implement this condition, it is extremely fast compared to non linear methods.5.1. I/O MODELS: SPECTRAL ANALYSIS 45
5.1.4 Other Spectral Analysis Tecniques
After applying the standard SA approach, to try to overcome the limits of this
Cunningham method we used a new spectral analysis algorithm, which was re-
cently adjusted with leucine PET data: Spectral Analysis Iterative Filter
(SAIF) [18]. The starting point of this idea is the Turkheimer SA method, in
particular the double Turkheimer ﬁlter: with this method, all the identiﬁed com-
ponents with exponents greater than zero but less than βlowcut−off are assumed
to have been shifted from β0 due to noise in the data and components with expo-
nents greater than βhighcut−off are assumed to be connected to the blood volume
term. The two values βlow and βhigh deﬁne che cut-oﬀ interval and the goal of
the method is to eliminate all the components outside this interval and thereby
improving the quality of estimation for the trapping component α0 and for the Vb.
The SAIF method starting from this idea deﬁnes a correction ﬁltering composed
of two parts: in the ﬁrst, it removes the equilibrating components and new values
of the trapping component and Vb are estimated; in the second part the trapping
and the blood volume are removed from the data and the method re-estimates the
equilibrating components. These two steps are repeated until a stabilization of
the WRSS is reached and its name is due to the presence of this iterative cycle. So
the operative mechanism of the SAIF can be summerized in the following points:
1. traditional Cunningham SA, in order to provide the spectrum for the ﬁlter-
ing process;
2. selection of the cut-oﬀ interval;
3. double Turkheimer ﬁlter, so that new values of the trapping and Vb are
estimated (1st ﬁltering);
4. new estimation of the equilibrating components, using the same principles
and values of the 1st ﬁltering (2nd ﬁltering);
5. stop criterion, in particular the WRSS variation is used; in this way the a
priori deﬁnition of the number of iterations is avoid and only the charac-
teristics of data determine when the cycle must be stopped.46 5. MODELS AND METHODS
So this algorithm attempt to strike a balance between the equilibrating compo-
nents and the limit components by delating those components which are outside
the cut-oﬀ interval. It is immediatly clear that the choice of this interval is one
of the most important and crucial element for the success of the algorithm, in
fact it greatly inﬂuences the ﬁnal spectrum, and therefore also the estimates of
the diﬀerent variables. Unluckly there is not yet a general method to ﬁx the end-
points of this cut-oﬀ interval, and the best way is to test diﬀerent values for βlow
and βhigh looking for the ones which give the lowest bias, the best distribution of
parameters and precision, as well as the lowest number of iterations. After testing
various combinations of these two values, we tried to ﬁnd a possible method that
could allow the endpoints to be ﬁxed respecting the caracteristics of the PET
data of each subject. We arrived at the formulation of one possible idea using the
results of the traditional Cunningham SA and the deﬁnition of the probability
density function. After ﬁxing a speciﬁc beta grid, for each subject we applied the
SA approach to all the regions of interest and represented through an istogram
the state of the beta values corresponding to the equilibrating components. This
showed some normal distributions (one or two peaks) and so starting from this
observation, we decided to compute a probability density estimate of represented
distribution, using the ksdensity function of Matlab. If the number of detected
peaks was two or more, we chose the beta values corresponding to the highest
ones and used them as endpoints for the cut-oﬀ interval, instead if only one peak
was present in the probability density function we reported this beta value as
βhigh and for the βlow we chose one value among the ﬁrst values of the ﬁxed beta
grid. This idea has to be improved and further tested, also using diﬀerent PET
data and ﬁxed beta grids.
Lastly, we tested also another spectral analysis algorithm, which is a modi-
ﬁcation of the Cunningham method: it has two diﬀerent input functions, one is
the usually plasma concentration Cp(t), instead the other is given by the total
plasma concentration, i.e the plasma with the metabolites Ctp(t). This is diﬀerent
from the total blood Cb(t), because Ctp(t) is corrected for the haematocrit.
We tried this double input algorithm with the purpose of inquiring into the inﬂu-
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since their presence was considerable. So we have now two diﬀerent convolutions
even if the esponential term is the same, the estimated parameters are the blood
term Vb for β → ∞, α values connected to the plasma input funcion and η values
proportional to the total plasma input. Also in this case, the values found in
corrispondence to β = 0 represent the presence of an irreversible process.
The total activity in the ROI Ctiss(t) can be written as:
Ctiss(t) =
M  
j=1
αj   Cp(t) ⊗ e
−βjt +
M  
j=1
ηj   Ctp(t) ⊗ e
−βjt + VbCb(t)
=α0  
  t
0
Cp(τ)dτ +
M  
j=2
αj  
  t
0
Cp(τ)e
−βj(t−τ)dτ+
η0  
  t
0
Ctp(τ)dτ +
M  
j=2
ηj  
  t
0
Ctp(τ)e
−βj(t−τ)dτ + VbCb(t)
(5.10)
with β1 = 0.
5.2 Compartmental Models for [11C]SCH442416
Spectral Analysis, that we have seen in the ﬁrst part of the chapter and used as
ﬁrst method for the analysis of our [11C]SCH442416 data, is an important exam-
ple of a noncompartmental modeling approach that has been widely applied in
PET studies. Starting from results obtained with this I/O model, that suggests
the minimum number of compartments to be used to describe the kinetic of the
tracer, we then considered the tradional approach for the modeling PET tracer
wich is based on compartmental models and tried to choose the best represen-
tation for our data. These compartmental models requires an arterial blood or
plasma input function, wich is known and considered without errors, and make
a series of general assumptions, e.g. that there is instantaneous mixing within
the individual compartments, that the concentration of tracer is small enough
so that it does not perturb the system under study, that tissue is homogeneus.
Under these conditions the system is described by a set of ﬁrst order linear dif-
ferential equations and parameter estimates may be obtained by the weighted
least squares ﬁtting of these models to measured PET data, as we will see in the
following sections.48 5. MODELS AND METHODS
5.2.1 Traditional Compartmental Models
Most quantitative PET studies of radioligand binding to neuroreceptors in brain
are analysed using models derived from the three-tissue compartment model for-
mulated by Mintun et al. in 1984. The three-tissue compartments account for the
radioligand in terms of free (Cf(t)), non-speciﬁcally bound (Cns(t)) and speciﬁ-
cally bound (Cs(t)) pools, while Cp(t) is the plasma concentration corrected for
the presence of metabolites. Parameters K1 [ml ml−1 min−1] and k2 [min−1] rep-
resent rate constant of ligand transfer from plasma to tissue and viceversa, k3
[min−1] represents the transfer of tracer to the speciﬁc compartment from the
free one and k4 [min−1] is the return, while k5 [min−1] is the transfer of the tracer
from the free to the non speciﬁc pool and k6 [min−1] is the return (Figure 5.3)
[19].
Figure 5.3: Three-tissue six-rate costant compartmental model normally used for
neuroreceptors syudies
In practice, because of the noise in typical PET data, it is not possible to
identify the full model within individual regions, unless additional constraints are
applied or supplementary data are available and so usually it is used the lower or-
der two-tissue compartment conﬁguration which is based on the assumption that
the free and non speciﬁc tracer kinetics are indistinguishable (Cf(t) and Cns(t)).
The two-tissue four-rate constant compartmental model (4K model) was
the ﬁrst representation that we used to describe the tracer radioactivity in the
brain, even if it was soon rejected since the results of the I/O model (as we will
see in Chapter 6) showed the presence of an irreversible trapping of the tracer,
component that was signiﬁcant for almost all the 6 subjects. In this model the5.2. COMPARTMENTAL MODELS FOR [11C]SCH442416 49
exchange rates k5 and k6 are suﬃciently rapid in comparison to the other rates
of the model and so there is the simpliﬁcation Cf+ns(t) = Cf(t) + Cns(t) i.e the
free and non speciﬁc binding tracer concentration are considered together, as a
unique pool (Figure 5.4).
Figure 5.4: 4K model
The model equations are:
dCf+ns(t)
dt
= K1Cp(t) + k4Cs(t) − (k2 + k3)Cf+ns(t)
dCs(t)
dt
= k3Cf+ns(t) − k4Cs(t)
(5.11)
with initial conditions Cf+ns(0) = Cs(0) = 0.
The PET scanner measure is given by
C(t) = (1 − Vb)[Cf+ns(t) + Cs(t)] + VbCb(t) (5.12)
where C(t) is the total activity in the ROI, Cb(t) is the whole blood tracer con-
centration and Vb [unitless], as seen previously for the SA, is the fraction of total
volume occupied by blood. All ﬁve model parameters, K1, k2, k3, k4 and Vb are a
priori uniquely identiﬁable. The 4K model was tested to have a whole view, but
we focused more our attention on other two irreversible models deriving from this
one: the 3K and the 5K models.
The two-tissue three-rate constant compartmental model (3K model) was50 5. MODELS AND METHODS
ﬁrst proposed by Sokoloﬀ et al. (1977) to describe the [18F]FDG kinetic in human
and it main caracteristic is that it assumes the tracer is trapped in the tissue
during the experiment (Figure 5.5).
Figure 5.5: 3K compartmental model
With some renumbering the equations of the model are
dCf+ns(t)
dt
= K1Cp(t) − (k2 + k3)Cf+ns(t)
dCs(t)
dt
= k3Cf+ns(t)
(5.13)
with initial conditions Cf+ns(0) = Cs(0) = 0, while the PET measure is the same
of the Equation 5.12, given by
C(t) = (1 − Vb)[Cf+ns(t) + Cs(t)] + VbCb(t) (5.14)
For this case it is interesting to see the correlation between the compartmental
and the I/O model, also to better understand how it is possible to interpretate
the numerical SA results and to ﬁnd the diﬀerent rate costants knowing the
structure of the system. In this situation the spectrum given by the SA tecnique
consists of three components: a trapping component (irreversible compartment),
an equilibrating component (reversible compartment) and a blood term Vb, for
β → ∞, accounting for the vasculature in the ROI.
The associated SA equation is
C(t) = α0
  t
0
Cp(τ)dτ + α1
  t
0
Cp(τ)   e
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while the measurement equation derived from the 3K model after the solution of
the diﬀerential system (Equation 5.13) is
C(t) =
K1k3
k2 + k3
  t
0
Cp(τ)dτ +
K1k2
k2 + k3
  t
0
Cp(τ) e
−(k2+k3)(t−τ)dτ +VbCb(t) (5.16)
So the correlation is immediatly clear and given by:

    
    
K1k3
k2+k3 = α0
K1k2
k2+k3 = α1
k2 + k3 = β1
(5.17)
The same procedure can be done also for the other models in order to clearly
identify the relationship between the α and β values of the spectrum and the rate
costants of the speciﬁc structure. The 3K model is a priori uniquely identiﬁable
and its parameters are estimate using a weighted non-linear least squares method,
as we will explain in details in Section 5.2.3.
The three-tissue ﬁve-rate costant compartmental model (5K model) can
be viewed as an extension of the model proposed by Sokoloﬀ: the diﬀerence with
this one lies in its explicit accounting of a non-speciﬁcally bound pool. The rate
costant k5 [min−1] describes the exchange between this compartement and the
free one, while k6 [min−1] represents the return; moreover, like in the 3K model,
it is supposed there is an irreversible trapping of the tracer in the speciﬁcally
bound pool (Figure 5.6).
This model is described by the following equations:
dCf(t)
dt
= K1Cp(t) + k6Cns(t) − (k2 + k3 + k5)Cf(t)
dCns(t)
dt
= k5Cf(t) − k6Cns(t)
dCs(t)
dt
= k3Cf(t)
(5.18)
with initial conditions Cf(0) = Cns(0) = Cs(0) = 0.
The measurement equation is deﬁned as
C(t) = (1 − Vb)[Cf(t) + Cns(t) + Cs(t)] + VbCb(t) (5.19)52 5. MODELS AND METHODS
Figure 5.6: 5K compartmental model
Also this model with some adjustments is a priori uniquely identiﬁable: we
have to underline that the parameter K1, that we ﬁnd in all these three model
and represents the exchange between plasma and tissue (plasma clearance), is
instead a composite parameter (a sort of macroparameter) which can be written
as
K1 = k1  
Vplasma
Vtissue
(5.20)
where k1 is the real rate costant, Vplasma ans Vtissue are respectively the volume
of plasma and tissue, which are all unknown. This is the reason why K1 has a
diﬀerent unit of measure in comparison with the other rate costant parameters,
i.e mlplasma   ml
−1
tissue   min−1. We make this combination in order to have an a
priori uniquely identiﬁable model, since if we don’t reunite we have too many
parameters that can not be identiﬁed with the equation in our hand.
For each of the three tested models, after the estimation of the diﬀerent mi-
croparameters, we calculated some more robust macroparameters, in fact some-
times it is more useful to employ combinations of the single parameters to repre-
sent the observed data. These macroparameters provide several information such
as the behavior of target molecule and physiological function.
In particular we calculated:
• Distribution Volume Vd[mlplasma/mltissue] : it is usually deﬁned for reversible
systems and it is described as the ratio of the tracer concentration in tissue5.2. COMPARTMENTAL MODELS FOR [11C]SCH442416 53
to that in plasma in steady state;
• Net Uptake Rate Constant (fractional uptake) K[mlplasma/mltissue/min]: it
is usually deﬁned when there is an irreversible process and it is the amount
of accumulated tracer in relation to the amount of tracer that has been
available in plasma, i.e the fractional rate costant of irreversible binding of
tracer to the speciﬁc receptors.
For each model, we have a diﬀerent formulation of these two macroparameters.
For the 4K model they are given by:
Vd =
Cf+ns + Cs
Cp
         
ss
=
K1
k2
 
1 +
k3
k4
 
(5.21a)
K =
K1k3
(k2 + k3)
(5.21b)
For the 3K model they are given by:
Vd =
Cf+ns
Cp
         
ss
=
K1
(k2 + k3)
(5.22a)
K =
K1k3
(k2 + k3)
(5.22b)
Lastly, for the 5K model:
Vd =
Cf + Cns
Cp
         
ss
=
K1
(k2 + k3)
 
1 +
k5
k6
 
(5.23a)
K =
K1k3
(k2 + k3)
(5.23b)
These two macroparameters, together with the plasma clearance K1, are the
same that we can evaluate also with the SA approach, as we have seen before.54 5. MODELS AND METHODS
5.2.2 New Compartmental Models
After a more detailed observation of the summed PET images (from 0 to 90 mins,
but also other intervals were tested), in all subjects we found a signiﬁcant amount
of blood especially in the occipital lobe area: as we will explain and discuss in
the next chapter, we performed a quantitative analysis of this area, and starting
from these results we proposed some new and particular compartmental models
to describe the kinetic behavior of [11C]SCH442416.
We are undergoing to present four diﬀerent models, they all account for the
high presence of blood, in which there are many A2A receptors that are the target
subtype of our tracer and that are both connected to the blood vessels and human
platelets.
The ﬁrst model that we propose (Model 1) is a four-compartment ﬁve-rate
costant model, in particular one compartment accounts for plasma tracer con-
centration (Cp(t)), one is for the tissue concentration (C3(t)), the other two com-
partments are also connected to blood and not to tissue as previously (C1(t)
and C2(t)) and this is the innovation in comparison with the tradional compart-
mental models used for neuroreceptor binding studies (Figure 5.7). Moreover, in
accordance with the main result of SA tecnique, we suppose the presence of an
irreversible process of the tracer, but the trapping is in the vascular part (so it
represents a non-speciﬁc binding): it is described by the rate costant k3[min−1].
The other rate costants k1 [min−1] and k2 [min−1] describe the exchanges inside
the blood vessels, while K5 [mlplasma   ml
−1
tissue   min−1] and k6 [min−1] represent
the exchange through the blood-brain barrier BBB from plasma to tissue.5.2. COMPARTMENTAL MODELS FOR [11C]SCH442416 55
Figure 5.7: Model 1
The equations that describe the model are:
dC1(t)
dt
= k1Cp(t) − k2C1(t)
dC2(t)
dt
= k3Cp(t)
dC3(t)
dt
= K5Cp(t) − k6C3(t)
(5.24)
with initial conditions C1(0) = C2(0) = C3(0) = 0.
The new PET scanner measure is given by
C(t) = (1 − Vb)C3(t) + Vb[C1(t) + C2(t)] + VbCb(t) (5.25)
This structure is a homogenous kinetic model and so there is not the problem
of identiﬁability, in fact it is a priori uniquely identiﬁable (for all details see
Appendix A). The parameters of interest that we are looking for in this case are
deﬁned as
Fractional Uptake = K = k3 (5.26a)
Distribution Volume = Vd =
K5
k6
(5.26b)56 5. MODELS AND METHODS
while the unidirectional clearance of tracer from blood to tissue is now given by
the macroparameter K5.
Starting from this conﬁguration, we tried a second model (Model 2) with
the same number of costant rates and compartments but connected each other in
a diﬀerent way: the tissue is described by a two-tissue four-rate costant structure,
while the irreversible trapping is still due to blood presence and it is in the vascular
part (Figure 5.8). The rate costants K1 [mlplasma ml
−1
tissue min−1] and k2 [min−1]
describe the transport through the BBB from plasma to the free-nonspeciﬁcally
bound pool (C1(t) = Cf+ns(t)) and back, k3 [min−1] and k4 [min−1] describe
the exchange between this late pool and the speciﬁcally bound compartment and
return (C2(t) = Cs(t)), lastly k5 [min−1] describes the irreversible process inside
blood (C3(t)).
Figure 5.8: Model 2
The model is described by the following system of equations:
dC1(t)
dt
= K1Cp(t) + k4C2(t) − (k2 + k3)C1(t)
dC2(t)
dt
= k3C1(t) − k4C2(t)
dC3(t)
dt
= k5Cp(t)
(5.27)
The initial conditions are the same C1(0) = C2(0) = C3(0) = 0, while the mea-5.2. COMPARTMENTAL MODELS FOR [11C]SCH442416 57
surament equation is given by
C(t) = (1 − Vb)[C1(t) + C2(t)] + VbC3(t) + VbCb(t) (5.28)
Also this compartmental model is uniquely identiﬁable and the macroparameters
that we can calculate are deﬁned as
K = k3 (5.29a)
Vd =
K1
k2
 
1 +
k3
k4
 
(5.29b)
and, as previously, the unidirectional clearance is given by K1.
After the analysis of the time course of the unmetabolized fraction of plasma
and the results of spectral analysis with two input functions (described in the
previous section), we proposed other two compartmental conﬁgurations, that still
account for the signiﬁcant presence of blood.
So the third new model (Model 3) has two diﬀerent plasma input functions, i.e
the plasma tracer concentration, corrected for haematocrit and for the presence of
metabolites (Cp(t), parent plasma) and the total plasma tracer concentration, un-
corrected for metabolites (Ctp(t), total plasma). We suppose that the irreversible
trapping is due total blood, so connected to the presence of metabolites, and de-
scribed by the rate costant k3, while a tissue and a blood compartment exchanges
with parent plasma input: K5 and k6 describe the transport from plasma to tissue
and back, k1 and k2 represent the exchange inside blood part (Figure 5.9).
K5, with measurement unit[mlplasma ml
−1
tissue min−1], represents the plasma clear-
ance of tracer from blood to tissue, while the other rate costants are expressed
as [min−1].
The equations that describe the new model are:
dC1(t)
dt
= k1Cp(t) − k2C1(t)
dC2(t)
dt
= k3Ctp(t)
dC3(t)
dt
= K5Cp(t) − k6C3(t)
(5.30)
with initial conditions C1(0) = C2(0) = C3(0) = 0 and PET misure given by
C(t) = (1 − Vb)C3(t) + Vb[C1(t) + C2(t)] + VbCb(t) (5.31)58 5. MODELS AND METHODS
Figure 5.9: Model 3
The two combined parameters of interest are the same of Equation 5.26, in fact
they are deﬁned as:
K = k3 (5.32a)
Vd =
K5
k6
(5.32b)
Finally, we propose a fourth model (Model 4) which as the same input func-
tions, the same type of comparments and rate costants of Model 3, but now the
irreversible process is connected to plasma concentration and not to metabolites
(Figure 5.10). This comparmental model is described by
dC1(t)
dt
= k3Cp(t)
dC2(t)
dt
= k1Ctp(t) − k2C2(t)
dC3(t)
dt
= K5Cp(t) − k6C3(t)
(5.33)
with initial conditions C1(0) = C2(0) = C3(0) = 0.
The PET scanner measure and the deﬁnition of macroparameters are the same
of Equation 4.31 and Equation 4.32 respectively.5.3. PARAMETER ESTIMATION 59
Figure 5.10: Model 4
5.3 Parameter Estimation
The kinetic components of the I/O model were estimated via nonnegative linear
weigthed least squares, as described in section 5.1.1. Instead, all compartmental
models require nonlinear identiﬁcation and in this study all unknown parameters
were estimated by weighted nonlinear least squares (WNLLS), ﬁrst they were
implemented in SAAM II and in a second moment in Matlab.
Tissue activity curves are described by
C
obs
i (tj) = Ci(tj) + e(tj) (5.34)
where j = 1,2,    ,N and N is the number of time points (number of data),
tj is the midscan time, Ci is the measured radioactivity concentration at time
tj and e is the measurement error at time tj. Error is assumed to be additive,
uncorrelated, Gaussian, zero mean and with a variance given by
σ
2(tj) = γ
Cobs
i (tj)
∆tj
(5.35)
where ∆tj is the length of the scanning interval relative to Cobs
i (tj) and γ is the
unknown proportionality costant that has to be estimated a posteriori as:
γ =
WRSS(ˆ p)
N − P
(5.36)60 5. MODELS AND METHODS
WRSS(ˆ p) is the weighted residual sum of squares evaluated in corrispondence of
the vector of estimated model parameters (the dimension of this vector is P): it
is given by
WRSS(ˆ p) =
N  
j=1
wj
 
C
obs
i (tj) − Ci(ˆ p,tj)
 
(5.37)
where wj is the weight of the jth datum.
In our work, weigths were chosen as the inverse of the variance, i.e
wj =
∆tj
Cobs
j (tj)
(5.38)
and since we observed for some ROIs high weights in correspondence to the ﬁrst
PET data, we decided to use a threshold taking the maximum value of the last
four weights: this threshold represents the maximum value that the weights can
reach. So the highest weights correspond to the data at the beginning, when there
is the arrival of the tracer, and in the ﬁnal part of the tracer activity, in this way
we weight these two part with the same accurancy.
Parameter precision was evaluated from the inverse of the Fisher information
matrix M:
COV (ˆ p) = γM
−1 (5.39)
both for the α values of the I/O model and the single microparameter of the com-
partmental models, using then the formula for the calculation of the coeﬃcient
of variation CV1. Instead for the estimate of the precision of macroparameters Vd
and K, if they are expressed as a combination of multiple microparameters, we
started from the variance-covariance matrix COV and used the propagation of
error. We calculated also the residuals and weighted residuals at time tj, which
are deﬁned as:
res(tj) = C
obs(tj) − C(ˆ p,tj) (5.40a)
wres(tj) =
Cobs(tj) − C(ˆ p,tj)
σ(tj)
(5.40b)
Residuals must reﬂect, if the model is correct, the assumptions on the measure-
ment error, i.e., to be a zero mean and independent process.
1The coeﬃcient of variation is given by: CV (ˆ p) =
SD(ˆ p)
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Finally, we evaluated also the Akaike Information Criterion, to compare the
diﬀerent models and it is deﬁned as:
AIC = Nln(WRSS(ˆ p)) + 2P (5.41)Chapter 6
Results
In this chapter we are going to present the main results that we found in our
[11C]SCH442416 data, using the diﬀerent types of models presented in the pre-
vious chapter. In particular we will focus on the results obtained with the I/O
model proposed by Cunningham and on the results found with the new four com-
partmental models that we proposed to describe the kinetic of this tracer in the
brain.
6.1 General Considerations on [11C]SCH442416
Data
As already explained in Chapter 4, all arterial signals were corrected for the delay
between the tracer arrival time in the brain and the arterial sampling site, and
were decay corrected to the time of injection.
While in a previous study on rats it was found that tracer preferentially dis-
tributed in plasma since its plasma-to-blood ratio was always > 1 during the ex-
perimental time, here for all the subjects we ﬁnd a ratio that starts from a value
> 1 but rapidly decreases for the ﬁrst 30 mins of the experiment, then there is
a steady state till the end of the experiment. This time course is consistent with
the presence of radiolabelled metabolites in blood. In humans, diﬀerently from
rats and monkeys, we can observe a rapid metabolism especially in the ﬁrst part
and after 30 mins the unmetabolized fraction accounts for less than 30% of total
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plasma activity (see Figure 4.1, Chapter 4).
The PET data were corrected for the decay and the analysis of summed PET im-
ages shows a rapid uptake in all brain regions, even if the tracer accumulation in
the brain is not so high and fairly homogeneous, except for the Striatum (Caudate
Nucleus + Putamen)- Globus Pallidus areas, where the tracer highly accumulates,
in agreement with the selective distribution of A2A receptors within the brain.
As we can see from the tissue-time activity curves quoted for each subject at
the end of Chapter 4, the highest activity are found in Caudate and Putamen,
while other regions like Cerebellum, Anterior Cingulate Gyrus, Thalamus and
Brainstem present a rapid uptake, with a time course similar to the plasmatic
curve, probably because in these regions there is a small amount of adenosine A2A
subtype. Peak value is reached at about 1÷2 mins after the tracer injection and
values of concentration are similar between diﬀerent subjects, except for subject
1804 who presents lower values, especially for the peak. There is a considerable
inter-subject variability, in particular after 30 min from the beginning of the scan,
the curves present very diﬀerent courses:
- in subjects 2300, 1711 and 2241 there is a nearly constant concentration till
the end of the experiment for all the ROIs;
- in subjects 1814, 1804 and 1866 there is a more remarked irreversibly bound
activity, in fact the curve start to raise again.
From a more detail analysis of summed PET images we noticed the presence
of large vascular areas, even if usually blood inﬂuence is less signiﬁcant in this
type of images and this is the observation that, during the quantitative analysis,
has helped us to formulate new comportmental models, very diﬀerent from the
traditional ones (Figure 6.1).
Lastly, we have to underline that two of the six subjects involved in this study
presented some problems during the experiment, in particular they are subject
number 2300 (healthy control), who was discovered to have a brain injury, and
number 1804 (PD): so in this chapter we will present also the results concerning
these subjects, but the diﬀerent considerations are esentially based on the other
four patients.6.1. GENERAL CONSIDERATIONS ON [11C]SCH442416 DATA 65
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Figure 6.1: Diﬀerent slices of summed PET images (from 0 to 90 mins), which
show the signiﬁcant amount of vasculature in the brain connected to the
[11C]SCH442416 tracer, especially in the occipital gyrus66 6. RESULTS
6.2 I/O model results
6.2.1 Traditional Spectral Analysis
The traditional SA approach by Cunningham was the ﬁrst noncompartmental
approach that we applied in order to determine the number of necessary compo-
nents to describe the kinetic of the tracer into the brain. It provided us important
information that guided the selection of the most appropriate compartmental
structure; moreover we applied this tecnique to compare our results with ones
already present in literature.
This ﬁrst step to implement SA is the choice of the beta grid, as explained in
Section 5.1.2 (see Table 5.1). The DiStefano distribution (ﬁrst beta grid), which
is usually used in SA, presented some problems with our PET data, in fact the
SA approach with this grid was not able to detect the diﬀerent spectral lines
and the α components that it found had very low precision. The result was an
underestimation of the number of spectral lines and a bad ﬁt of the data for all
subjects. To overcome these problems we used linear grids: the second beta grid
identiﬁed the diﬀerent α values with a good precision and good ﬁt for all the ROIs
of the six subjects, even if when it detected two adjacent lines, the coeﬃcient of
variation CV of these αs became very high.
Starting from these results, observing that subjects 1711 and 2241 had slow ki-
netics and for many ROIs the line connected to the ﬁrst nonzero beta of the grid
was identiﬁed, we decided to thicken the ﬁrst part of the grid (slow components)
in order to characterize better the distribution of betasand the potential presence
of the trapping (third beta grid).
The model estimated curves with this grid ﬁtted well the data and the low-
frequency components were better detected, but identiﬁng a larger number of
components, the precision of some alphas decreased.
To complete the possibilities, we also tried another ﬁx grid, starting from the
distribution of βs suggested by DiStefano and changing the value of the esponent
(from 1
M−1 to 1
1−M): in this way we did not ﬁnd problems, e.g with the ﬁt of the
data, and also the precisions were similar to the ones found with the other two
grids. In conclusion for all these reasons we decided to use the third beta grid as6.2. I/O MODEL RESULTS 67
optimal grid for all the subjects and for all the diﬀerent SA approaches.
Each subject presents a particular behoviour, but a similar pattern can be found
between some of them: for the most part of the ROIs a component in corrispon-
dence to β = 0 was found, which indicates an irreversible trapping of the tracer,
even if, especially for subject 1711 and 2241 (who present a very similar pattern
in comparison with the others), this component has been shifted in the ﬁrst po-
sitions of the grid, probably due to noise in the data.
The obtained spectrum is fragmented since we have a discrete grid and the pres-
ence of double components in consecutive positions is present for all the subjects,
in fact frequently the algorithm splits the real value in two parts placed in the
closest possible positions of the best-ﬁtting value. Taking account of this problem
of “double lines”, we decided to consider as a unique component two adjacent
values, both for the intermediate lines and for the ones in the ﬁrst positions of
the beta grid, near to β = 0 (we consider them as still irreversible trapping).
Instead, the lines detected in corrispondence of the last points of grid were con-
sidered vascular noise and so connected to the blood volume component.
The number of detected lines on average and after this assumption is reported in
Table 6.1.
Subject Number of Spectral Lines
1 component for βj = 0
1814 1 intermediate component
1 component for βj → ∞
1 component for βj = 0 or very close
1711 2 intermediate components∗
1 component for βj → ∞
1 component for βj = 0 or very close
2241 2 intermediate components∗
1 component for βj → ∞
1 component for βj = 0
1804 1 intermediate component
1 component for βj → ∞68 6. RESULTS
1 component for βj = 0
1866 1 intermediate component
1 component for βj → ∞
1 component for βj = 0 or very close
2300 2 intermediate components
1 component for βj → ∞
Table 6.1: Number of spectral lines for each subject with the third beta grid.
∗ number of lines after the assumption regarding the doubling eﬀect (originally
we found for these two subjects 4 spectral lines)
The microparameter Vb was estimated with high precision and the average
value was 0.04÷0.05 [unitless] in agreement with values present in literature,
except for subject 2241 who presented a Vb two times higher. It does not belong
properly to the spectrum but can be confused with high-frequency components.
Remembering that the number of lines in the spectrum represents the optimal
number of compartments to be included in the structure model (low-frequency
component → irreversible compartment; intermediate frequency component →
reversible compartment), we can lastly summerize the behaviour of each subject
Table 6.2.
Subject Components
1 irreversible
1814 1 reversible (0.58±0.18)
blood content (Vb = 0.03±0.01)
1 irreversible
1711 1 reversible (0.03±0.02)
1 reversible (0.3±0.08)
blood content (Vb = 0.04±0.01)
1 irreversible
2241 1 reversible (0.01±0.01)
1 reversible (0.19±0.04)
blood content (Vb = 0.10±0.02)6.2. I/O MODEL RESULTS 69
1 irreversible
1804 1 reversible (0.67±0.19)
blood content (Vb = 0.03 ±0.01)
1 irreversible
1866 1 reversible (0.4±0.18)
blood content (Vb = 0.04 ±0.01)
1 irreversible
2300 1 reversible (0.01±0.03)
1 reversible (0.33±0.3)
blood content (Vb = 0.05 ±0.01)
Table 6.2: Average components found for each subject after analysing the results
in the light of the explained problems of SA approach (mean±sd)
The macroparameters of interest, i.e distribution volume Vd, unidirectional
clearance of tracer from blood to tissue K1 and the net uptake rate costant K for
the trapping of the tracer, were estimated with a good precision, and so presented
low CVs. However, for Vd values we found a great variability between the ROIs
of subjects 1711, 2241 and 2300, due to the presence of low components near 0:
probably for the estimation of this parameter it would have been better if we had
trascured these values.
In the next tables we report for each subject the values found with the SA ap-
proach using the optimal grid. In particular in Tables 5.3-5.8 we show the α values
without any assumptions in view of the future compartmental model, i.e they are
the values given by the lsqnonneg function as optimal ones. The most important
ROIs for our study are showed, considered separately in their left and right side.70 6. RESULTS
Table 6.3: Subject 1814, α values without any model assumptions.
α[mlml−1min−1], β[min−1],Vb[unitless]
ROI α β α β α β α β Vb
Cerebellumr 0.0120 0 0.0283 0.8238 0.0113 1.6 - - 0.0252
Cerebelluml 0.0119 0 0.0160 0.7058 0.0148 0.7176 0.0050 1.6 0.0249
G cing antl 0.0121 0 0.0135 0.6822 0.0136 0.6940 - - 0.0412
G cing antr 0.0113 0 0.0175 0.7176 - - - - 0.0312
CaudateNucll 0.0122 0 0.0134 0.5169 0.0121 0.5288 0.0143 1.6 0.0172
CaudateNuclr 0.0116 0 0.0119 0.4343 0.0203 0.4461 0.0000 1.6 0.0177
NuclAccumbl 0.0120 0 0.0032 0.3045 0.0114 0.3163 - - 0.0226
NuclAccumbr 0.0126 0 0.0016 0.3517 0.0241 0.3635 - - 0.0249
Putamenl 0.0136 0 0.0044 0.3635 0.0350 0.3753 - - 0.0273
Putamenr 0.0141 0 0.0158 0.3635 0.0209 0.3753 0.0061 1.6 0.0261
Thalamusl 0.0131 0 0.0214 0.8120 0.0197 1.6 - - 0.0229
Thalamusr 0.0123 0 0.0009 0.6468 0.0189 0.6586 0.0126 1.6 0.0232
Palliduml 0.0094 0 0.0109 0.2337 0.0039 1.6 - - 0.0308
Pallidumr 0.0100 0 0.0160 0.1275 0.0147 1.6 - - 0.0224
Table 6.4: Subject 1711, α values without any model assumptions.
α[mlml−1min−1], β[min−1],Vb[unitless]
ROI α β α β α β α β α β α β Vb
Cerebellumr 0.0095 0 0.0059 0.022 0.0071 0.033 0.0283 0.305 0.033 0.316 0.0175 1.6 0.0417
Cerebelluml 0.01 0 0.0018 0.0210 0.0119 0.033 0.0409 0.331 0.02599 0.3517 0.00327 1.6 0.0417
G cing antl 0.0094 0 0.0011 0.0331 0.0187 0.04491 0.0104 0.3281 0.0392 0.3399 - - 0.0603
G cing antr 0.0101 0 0.0003 0.0449 0.0222 0.05671 0.0493 0.3753 - - - - 0.0601
CaudateNucll 0.0117 0 0.0188 0.0567 0.0055 0.0685 0.0397 0.2691 0.0291 0.2809 - - 0.0354
CaudateNuclr 0 0 0.0108 0.0094 0.0097 0.0095 0.0690 0.2219 - - - - 0.0289
NuclAccumbl 0.0103 0 0.0202 0.0331 0.0347 0.2573 0.0284 0.2691 - - - - 0.0333
NuclAccumbr 0 0 0.0159 0.0095 0.0033 0.0213 0.0604 0.2101 0.0031 0.2219 - - 0.0354
Putamenl 0.0103 0 0.0101 0.0331 0.0105 0.045 0.03070 0.2219 0.0504 0.2337 - - 0.0441
Putamenr 0 0 0.01466 0.0087 0.0047 0.0088 0.0274 0.1039 0.0192 0.2691 0.0478 0.2809 0.0322
Thalamusl 0 0 0.009404 0.0077 0.0108 0.00770 0.0069 0.2573 0.062323 0.2691 3.69E-05 1.6 0.0502
Thalamusr 0 0 0.0132 0.00300 0.0015 0.00305 0.008 0.0331 0.007 0.2927 0.0666 0.3045 0.0479
Palliduml 0.0088 0 0.0041 0.0331 0.03 0.0449 0.0434 0.1865 0.0173 1.60000 - - 0.0184
Pallidumr 0 0 0.0065 0.0095 0.0213 0.02131 0.0399 0.1393 0.0358 1.60000 - - 0.01996.2. I/O MODEL RESULTS 71
Table 6.5: Subject 2241, α values without any model assumptions.
α[mlml−1min−1], β[min−1],Vb[unitless]
ROI α β α β α β α β α β Vb
Cerebellumr 0 0 0.0162 0.0078 0.0007 0.0078 0.0223 0.2337 0.0076 0.2455 0.0952
Cerebelluml 0 0 0.0065 0.0067 0.0103 0.0068 0.0230 0.2219 0.0090 0.2337 0.0972
G cing antl 0 0 0.0104 0.0062 0.0054 0.0062 0.0006 0.1865 0.0245 0.1983 0.0859
G cing antr 0.0053 0 0.0083 0.0095 0.0036 0.0213 0.0142 0.1393 0.0028 0.1511 0.1309
CaudateNucll 0 0 0.0099 0.0048 0.0049 0.0048 0.0107 0.2101 0.0419 0.2219 0.0822
CaudateNuclr 0 0 0.0122 0.0052 0.0016 0.0052 0.0181 0.2101 0.0393 0.2219 0.0574
NuclAccumbl 0.0132 0 0.0112 0.0921 0.0185 0.1039 - - - - 0.1218
NuclAccumbr 0.0112 0 0.0014 0.1039 0.0247 0.1157 - - - - 0.1023
Putamenl 0 0 0.0170 0.0078 0.0013 0.0078 0.0200 0.1983 0.0503 0.2101 0.0971
Putamenr 0.0095 0 0.0126 0.0449 0.0006 0.1865 0.0463 0.1983 - - 0.1092
Thalamusl 0 0 0.0008 0.0066 0.0173 0.0067 0.0345 0.3045 - - 0.1176
Thalamusr 0 0 0.0130 0.0049 0.0038 0.0050 0.0059 0.2337 0.0355 0.2455 0.0841
Palliduml 0.0125 0 0.0059 0.1275 0.0413 0.1393 - - - - 0.1078
Pallidumr 0 0 0.0009 0.0036 0.0139 0.0037 0.0212 0.1747 0.0301 0.1865 0.0905
Table 6.6: Subject 1866, α values without any model assumptions.
α[mlml−1min−1], β[min−1],Vb[unitless]
ROI α β α β α β α β α β Vb
Cerebellumr 0.0137 0 0.0319 0.5760 0.0131 0.5878 0.0124 1.6 - - 0.0399
Cerebelluml 0.0136 0 0.0256 0.5406 0.0146 0.5524 0.0195 1.6 - - 0.0392
G cing antr 0.0137 0 0.0285 0.4343 0.0160 1.6000 - - - - 0.0603
G cing antl 0.0146 0 0.0107 0.4933 0.0247 0.5051 - - - - 0.0421
CaudateNucll 0.0159 0 0.0248 0.2219 0.0300 0.2337 - - - - 0.0266
CaudateNuclr - - 0.0061 0.0001 0.0088 0.0001 0.0458 0.2337 0.0205 1.6 0.0217
NuclAccumbl - - 0.0012 0.0022 0.0143 0.0023 0.0318 0.2691 - - 0.0508
NuclAccumbr 0.0140 0 0.0088 0.1511 0.0001 0.1629 0.0358 1.1778 0.0368 1.6 0.0030
Putamenl 0.0153 0 0.0503 0.1983 0.0008 0.2101 0.0068 1.6 - - 0.0373
Putamenr 0.0159 0 0.0307 0.1865 0.0182 0.1983 - - - - 0.0376
Thalamusl 0.0127 0 0.0136 0.4107 0.0272 0.4225 - - - - 0.0334
Thalamusr 0.0139 0 0.0150 0.4343 0.0198 0.4461 0.0112 1.6 - - 0.0425
Palliduml 0.0118 0 0.0103 0.1039 0.0040 0.1157 0.0055 1.6 - - 0.0129
Pallidumr 0.0138 0 0.0358 0.1747 - - - - - - 0.020972 6. RESULTS
The precision of the trapping component and of Vb is good for all the sub-
jects, instead the alpha values have very high CVs. We also examined the ﬁt of the
data, that was good for all subjects except for subject 1804, in fact the descrip-
tion provided by the I/O model was not able to explain the data, expecially in
the ﬁrst part where the peak was not well described, even if we know from theory
that the ﬁt obtained with this type of model is the best we can reach([15],[16]).
However 1804 is one of the two subjects who presented some problems during the
experiment, in particular they are relative to the blood sampling, and so the data
are not so beliavable.
We also examined the weighted residuals, which were obtained from the multi-
plication of the residuals with the data weights: if the estimation is good, the
diﬀerence between the model-estimated curve and the measured data should be a
representation of a white noise process1, that means that weighted residuls should
be random, zero mean and in the range [-1;1]. The results seem to be consistent
with the expected trends and so this is a further veriﬁcation of the good estima-
tion obtained with the I/O model.
In Figure 6.2 we show some ﬁts and trends of weighted residuals, for a ROI with
a high number of receptors and for one of the poorest region.
1White noise is a random signal (or process) with a ﬂat power spectral density.6.2. I/O MODEL RESULTS 73
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Figure 6.2: Model estimated curves with SA and weighted residuals for left Cau-
date Nucleus and Anterior Cingulate Gyrus, for subjects 1711 and 1866, respec-
tively74 6. RESULTS
6.2.2 Alternative SA Algorithms
The second approach that we used for the quantiﬁcation of the kinetic components
and variables of interest was the Spectral Analysis Iterative Filter (SAIF): since
we had for some subjects a high number of spectral lines in the intermediate
part and the trapping was sometimes not well identiﬁed, we decided to try this
algorithm with the purpose of estimating with a better precision the diﬀerent
lines, also in the light of a possible compartmental model, and providing a good
quality estimates of the variables.
We used the same beta grid (third grid) already used for the traditional SA and
we tested diﬀerent values for both bounds of the cut-oﬀ interval: the choice of
these values is crucial for the application, because through this interval we decide
which are the lines of interest, containing the important information, and which
are due to noise. Moreover the cut-oﬀ interval inﬂuences the estimation of the
limit components, i.e the trapping and Vb. We tried to use for each subjects
the values altready present in literature, βlow = 0.03 βhigh = 0.3, but it was
immediatly clear that we could not apply to all subjects the same ﬁlter, since as
seen in the previous section, they had diﬀerent pattern and kinetics and with this
choice, especially for subject 1814 and 1866, many components remained out of
this interval. So after trying diﬀerent combinations for the cut-oﬀ values in order
to decide the best solution, we decided to use a more data-driven method, speciﬁc
for each subject, which we already explained in Section 5.1.3. It is connected to
the results of Cunningham SA and the estimation of a probability density function
through ksdensity.m of Matlab.
We tested this method only for three of the four reliable subjects (1814,1711 and
2241): we show in Figure 6.3 the results that we obtained for the cut-oﬀ values,
also in terms of spectral lines detected inside this interval. With this alternative
SA approach, we are able to overcome the problems of the traditional one, like
the double components, the fragmented spectrum and the shift of the low and
high-frequency components due to noise.6.2. I/O MODEL RESULTS 75
Figure 6.3: Possible values for the endpoints of the passaband ﬁlter using the SAIF;
the number of lines is refeared to those detected inside the interval. β[min−1]
In fact for each of these subjects we estimated with low bias and good precision
the irreversible trapping, the Vb term and 1÷2 intermediate components; the ﬁt
of data was good and the weighted residuals were in agreement with the expected
trend.
However for many ROIs the maximum number of ﬁlter iteration was reached
and often the intermediate lines were placed in corrispondence of the βhigh value,
index that probably the cut-oﬀ interval was not the optimal one. Further tests
are required to verify the reliable of this idea in order to deﬁne a data-driven
choice of the interval.
We also found that small changes in the value of the endpoints produced a high
decrease of the precision of the estimates. For all these reasons the SAIF approach
is a good algorithm, which provides us a good estimate of the parameters of
interest and helps us to deﬁne the best compartmental structure, but requires
the deﬁnition of a sturdy criterion to ﬁx the cut-oﬀ values, since the bias and
the accuracy depend on this choice. So we set apart this method since it was not
applicable to our data to ﬁnd a unique and interesting solution.76 6. RESULTS
Lastly, after observing that the amount of metabolites in the total plasma con-
centration was signiﬁcant and they rapidly appeared after the start of the study,
we tested the traditional SA but with a double input function: in this case the
unknown parameters, that we estimated through lsqnonneg.m of Matlab, were
αj correlated to the parent plasma concentration Cp(t) and ηj proportional to
the total plasma tracer activity Ctp(t). In this way we wanted to detect if some
lines of the spectrum were due to the presence of metabolites and in which part
they were collocated. We found a high inter-subject variability, in particular for
subjects 1711 and 2241 for the most part of the ROIs the line of trapping is con-
nected to metabolites, while for subjects 1814 and 1866 an opposite behaviour
was found, i.e the component for β = 0 was due to the tradional plasma input
function. Moreover a too high variability was detected also inside the same sub-
ject, probably because this tecnique is very sensitive to the presence of noise and
errors into the input function signals. We can summerize the results found, focus-
ing on the trapping and low-frequency components, in the following way, which
underlines the diﬀerent pattern between the four subjects:
∗ Subject 1814 → for 39 ROIs the line of irreversible trapping is connected
to Cp(t); for 37 ROIs the line due to metabolites is detected in position
β = 0.0095, while 3 ROIs have also other lines more than this one; for 2
ROIs the α components are not detected;
∗ Subject 1711 → for 24 ROIs the line of irreversible trapping is connected
to Ctp(t), and 22 of these present also other η  = 0; 10 ROIs don’t have
η  = 0 for β = 0 but present η values in corrispondence of low βs; 5 ROIs
do not present the irreversible trapping; for 9 ROIs there isn’t the spectral
line due to metabolites; 15 ROIs present an α value for β = 0.0095 or in
the adjacent positions;
∗ Subject 2241 → for 7 ROIs the line of irreversible trapping is connected
to Ctp(t) and for 21 ROIs low-frequency components near beta = 0 due to
Cp(t) are found; for 15 ROIs the line for β = 0 is not found; for 14 ROIs
the components due to metabolites is not present in the ﬁnal spectrum; for
21 ROIs η  = 0 are found in corrispondence of β = 0.0095 or 0.0213;6.2. I/O MODEL RESULTS 77
∗ Subject 1866 → for 28 ROIs the line of irreversible trapping is connected
to Ctp(t) and for 14 ROIs it is due to Cp(t); for 14 ROIs a η value for
β = 0.0095 is detected.
A part from the high variability, the model-estimated curves obtained with this
I/O model are able to follow and describe the data, even if the quality seems
the same of previous ﬁt with the traditional SA and also the trends of weighted
residuals are very similar. The following tables 6.7-10 show the values found for
the α and η values with the double input function; they are reported without any
model assumptions, i.e as given by the lsqnonneg of Matlab.7
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Table 6.7: Values for subject 1814 without any model assumptions. α,η[mlml−1min−1] , β[min−1],Vb[unitless]
ROI Cp(t) Ctp(t) Vb
alpha beta alpha beta alpha beta alpha beta eta beta eta beta eta beta eta beta eta beta
Cerebellumr 0.0006 0.0033 0.0017 0.3753 0.020 0.3871 0.0206 1.6 0.0076 0.0095 0 0 0 0 0 0 0 0 0.0267
Cerebelluml 0.0014 0.0032 0.0114 0.3753 0.012 0.3871 0.0152 1.6 0.0071 0.0095 0 0 0 0 0 0 0 0 0.0258
G cing antl 0.004 0.0029 0.0033 0.4579 0.022 0.4697 0 0 0.0058 0.0095 0 0 0 0 0 0 0 0 0.0431
G cing antr 0.002 0.0032 0.009 0.3399 0.005 0.3517 0.0034 1.6 0.0063 0.0095 0 0 0 0 0 0 0 0 0.0326
CaudateNucll 0.0021 0.0027 0.0208 0.2927 0.024 1.6 0 0 0.0068 0.0095 0 0 0 0 0 0 0 0 0.0174
CaudateNuclr 0.0023 0.0029 0.0302 0.3163 0.004 1.6 0 0 0.0063 0.0095 0 0 0 0 0 0 0 0 0.0181
NuclAccumbl 0.0053 0.003 0.0165 0.2691 0 0 0 0 0.0049 0.0095 0 0 0 0 0 0 0 0 0.0223
NuclAccumbr 0 0 0 0 0 0 0 0 0.0009 0.000 0.0034 0.0002 0.0178 0.1393 0.0004 0.1511 0.0125 0.6114 0.0258
Putamenl 0.0009 0.0032 0.0072 0.2337 0.0277 0.2455 0.0102 1.6 0.0083 0.0095 0 0 0 0 0 0 0 0 0.0276
Putamenr 0.0035 0.2337 0.029 0.2455 0.0174 1.6 0 0 0.0021 0 0.0023 0.0095 0.0058 0.0213 0 0 0 0 0.0258
Thalamusl 0.0022 0.0033 0.0057 0.3871 0.0125 0.3989 0.0231 1.6 0.0074 0.0095 0 0 0 0 0 0 0 0 0.0244
Thalamusr 0.0051 0.2455 0.0108 0.2573 0 0 0 0 0.007 0.0080 0.0006 0.0081 0.0188 1.6 0 0 0 0 0.0242
Palliduml 0.0164 0.1275 0 0 0 0 0 0 0.0043 0 0 0 0 0 0 0 0 0 0.0303
Pallidumr 0.0026 0.0022 0.0152 0.1039 0.0025 0.1157 0.015 1.6 0.0048 0.0095 0 0 0 0 0 0 0 0 0.02256
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Table 6.8: Values for subject 1711 without any model assumptions. α,η[mlml−1min−1] , β[min−1], Vb[unitless]
ROI Cp(t) Ctp(t) Vb
alpha beta alpha beta alpha beta alpha beta alpha beta eta beta eta beta eta beta eta beta
Cerebellumr 0.0068 0 0.0225 0.2691 0.0412 0.280931 0.0211 1.6 0 0 0.0002 0 0.0002 0.0331 0.0088 0.0449 0 0 0.2875
Cerebelluml 0.0577 0.2691 0.0103 0.4697 0.0061 1.6 0 0 0 0 0.0019 0 0.0016 0.0331 0.0101 0.0449 0.0036 0.5051 0.2882
G cing antl 0.0054 0.0449 0.0253 0.2809 0.0316 0.2927 0 0 0 0 0.002 0 0.0124 0.0567 0 0 0 0 0.4208
G cing antr 0.0077 0.0567 0.0486 0.3163 0.0058 0.3281 0 0 0 0 0.0023 0 0.0131 0.0685 0 0 0 0 0.4202
CaudateNucll 0.0275 0.0449 0.032 0.2573 0.0404 0.2691 0 0 0 0 0.0035 0 0.0006 0.0567 0 0 0 0 0.2451
CaudateNuclr 0.0185 0.0095 0.0164 0.2101 0.0533 0.2219 0 0 0 0 0.001 0.0213 0 0 0 0 0 0 0.2007
NuclAccumbl 0.0304 0.2219 0.041 0.2337 0 0 0 0 0 0 0.002 0 0.0149 0.0449 0.0008 0.056 0 0 0.2326
NuclAccumbr 0.0159 0.0095 0.0033 0.0213 0.0604 0.2101 0.003 0.2219 0 0 0 0 0 0 0 0 0 0 0.2458
Putamenl 0.0103 0 0.0101 0.0331 0.0105 0.0449 0.0307 0.2219 0.0504 0.2337 0 0 0 0 0 0 0 0 0.3062
Putamenr 0.0147 0.0088 0.0047 0.0088 0.0274 0.1039 0.0192 0.2691 0.0478 0.2809 0 0 0 0 0 0 0 0 0.2236
Thalamusl 0.0195 0.0081 0.0184 0.2573 0.0508 0.2691 0.0004 1.6 0 0 0.0004 0.0095 0 0 0 0 0 0 0.3486
Thalamusr 0.0003 0.0036 0.0138 0.0036 0.0754 0.2927 0 0 0 0 0.0054 0.0567 0 0 0 0 0 0 0.3333
Palliduml 0.0226 0.0331 0.0134 0.0449 0.0174 0.1747 0.0288 0.1865 0 0 0.0025 0 0.0146 1.6 0 0 0 0 0.1278
Pallidumr 0.0066 0.0095 0.0213 0.0213 0.0398 0.1393 0.0358 1.6 0 0 0 0 0 0 0 0 0 0 0.13828
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Table 6.9: Values for subject 2241 without any model assumptions. α,η[mlml−1min−1] , β[min−1], Vb[unitless]
ROI Cp(t) Ctp(t) Vb
alpha beta alpha beta alpha beta alpha beta eta beta eta beta eta beta eta beta eta beta
Cerebellumr 0.0157 0.0083 0.0289 0.2337 0.0011 0.2455 0 0.0008 0.0213 0 0 0 0 0 0 0 0 0.6618
Cerebelluml 0.0115 0.0095 0.0083 0.2101 0.0249 0.2219 0 0.0036 0.0213 0 0 0 0 0 0 0 0 0.6757
G cing antl 0.0104 0.0062 0.0054 0.0062 0.0006 0.1865 0.0245 0.1983 0 0 0 0 0 0 0 0 0 0 0.5965
G cing antr 0.0031 0.0213 0.0205 0.1393 0 0 0 0 0.0037 0.0213 0.0058 0.0331 0 0 0 0 0 0 0.9063
CaudateNucll 0.01 0.0049 0.0053 0.00107 0.0117 0.0419 0.0117 0 0 0 0 0 0 0 0 0 0 0.5708
CaudateNuclr 0.0068 0.0083 0.0582 0.2101 0.0004 0.2219 0 0.0045 0.0213 0 0 0 0 0 0 0 0 0.4021
NuclAccumbl 0.0071 0.0567 0.028 0.0685 0 0 0 0 0.004 0 0 0 0 0 0 0 0 0 0.8868
NuclAccumbr 0 0 0 0 0 0 0 0 0.0013 0 0.00001 0.0095 0.0017 0.0213 0.0049 0.1393 0.0247 0.1511 0.7132
Putamenl 0.017 0.0078 0.0013 0.0078 0.02 0.1983 0.0504 0.2101 0 0 0 0 0 0 0 0 0 0 0.6743
Putamenr 0.0059 0.0331 0.0516 0.1865 0 0 0 0 0.0013 0 0.0085 0.0449 0 0 0 0 0 0 0.7597
Thalamusl 0.0122 0.0095 0.0009 0.2809 0.0349 0.2927 0 0.004 0.0213 0 0 0 0 0 0 0 0 0.8160
Thalamusr 0.0166 0.0051 0.0081 0.2337 0.0333 0.2455 0 0.0002 0.0095 0 0 0 0 0 0 0 0 0.5840
Palliduml 0.0084 0.1393 0 0 0 0 0 0 0.0019 0 0.0419 0.1629 0 0 0 0 0 0 0.7667
Pallidumr 0.0123 0.0058 0.0359 0.1747 0.0159 0.1865 0 0.0016 0.0095 0 0 0 0 0 0 0 0 0.63136
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Table 6.10: Values for subject 1866 without any model assumptions. α,η[mlml−1min−1] , β[min−1], Vb[unitless]
ROI Cp(t) Ctp(t) Vb
alpha beta alpha beta alpha beta alpha beta eta beta eta beta eta beta
Cerebellumr 0.0052 0.2809 0.0222 0.2927 0.0307 1.1778 0.0016 1.6 0.0059 0.0073 0.0031 0.0073 0 0 0.043
Cerebelluml 0.0263 0.2691 0.0107 0.953585 0.0207 1.6 0 0 0.0001 0.0067 0.0087 0.0067 0 0 0.042
G cing antl 0.0229 0.2927 0.0037 0.3045 0.0054 1.0008 0.0054 1.0126 0.0095 0.0092 0.0009 0.0092 0 0 0.0442
G cing antr 0.0157 0.1865 0.0023 0.8356 0.0195 0.8474 0 0 0.0027 0.0081 0.0065 0.0081 0.0067 1.0952 0.0626
CaudateNucll 0.0563 0.1983 0 0 0 0 0 0 0.0028 0.0095 0.0085 0.0095 0 0 0.0278
CaudateNuclr 0.0033 0.0050 0.0269 0.2101 0.0199 0.2219 0.0221 1.6 0.0087 0.0095 0 0 0 0 0.0216
NuclAccumbl 0.0099 0.0048 0.0092 0.2455 0.023 0.2573 0 0 0.0043 0.0095 0 0 0 0 0.0511
NuclAccumbr 0.0101 0.0567 0.0046 0.0685 0.040 1.1778 0.0331 1.6 0.0063 0 0 0 0 0 0.0034
Putamenl 0.0007 0.0046 0.0502 0.1747 0.0019 0.1865 0.0106 1.6 0.0105 0.0095 0 0 0 0 0.0372
Putamenr 0.0325 0.1511 0.0177 0.1629 0 0 0 0 0.0103 0.0076 0.0001 0.0076 0.0038 1.6 0.0382
Thalamusl 0.0254 0.2573 0..0075 0.2691 0.0075 1.0244 0.003 1.0362 0.0057 0.0070 0.0029 0.0070 0 0 0.0356
Thalamusr 0.0305 0.2809 0.0193 1.6 0 0 0 0 0.0055 0.0082 0.0043 0.0082 0 0 0.0444
Palliduml 0.0161 0.0685 0.004 0.0803 0 0 0 0 0.0053 0 0.0039 1.6 0 0 0.0133
Pallidumr 0.0397 0.1275 0 0 0 0 0 0 0.0032 0.0023 0.0041 0.0023 0 0 0.022482 6. RESULTS
6.2.3 Spectral Analysis and ROI blood
As explained in the ﬁrst section of this chapter, the amount of blood in summed
PET images is signiﬁcant: since these areas were well localizated, we decided to
draw them and to consider these ones as new ROIs, called “ROIs blood”. So
for each subject we have a new ROI, which contains in prevalence blood, since,
drawing these regions, we tried to maximize the vascular presence.
It is an additional ROI and so, as for the others, we applied the traditional SA
approach, with the purpose to identify if some spectral lines were due to the
blood presence. In this case we will understand which lines contain the blood
information. As expected, the time-activity curve for this kind of ROI had a
course which was similar to the total blood curve Cb(t), with a reduced peak
value, as we can see in Figure 6.4.
Figure 6.4: Comparison between the total blood concentration Cb(t), the parent
plasma concentration Cp(t) and the signal extracted from ROI blood. Data are
related to subject (Healthy control)
Except for subject 1711, who, as we have already seen, has a large number
of spectral lines for each ROI and is enriched in information in comparison with
the other ones, we found a similar pattern in all subjects and the results of this6.2. I/O MODEL RESULTS 83
tecnique can be summerized in the following way:
Subject Number of Spectral Lines
1 irreversible component for β = 0
1814 1 reversible component for β = 0.08 (very low amplitude)
blood content Vb = 0.22
1 irreversible component for β = 0
1711 1 reversible component for β = 0.03
1 reversible component for β = 0.3
blood content Vb = 0.5
1 irreversible component for β = 0 (very low amplitude)
2241 1 reversible component for β = 0.02
blood content Vb = 0.63
1 irreversible component for β = 0
1804 1 reversible component for β = 0.1 (low amplitude)
blood content Vb = 0.41
1 irreversible component for β = 0
1866 1 reversible component for β = 0.17
blood content Vb = 0.4
1 irreversible component for β = 0
2300 1 reversible component for β = 0.07
blood content Vb = 0.37
Table 6.11: Results of SA approach for ROIs blood
From the analysis of these results, it is immediatly clear that the low-frequency
components, i.e for β = 0 or very close, are connected to the presence of blood
inside the diﬀerent ROIs. They reﬂect the tracer activity in blood and not in the
tissue as previously thought. So only one line describes and reﬂects the activity
of the tracer inside the tissue. This can be clearly show in Figure 6.5.84 6. RESULTS
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Figure 6.5: Comparison between the spectral lines found for the ROI blood (bot-
tom) and the lines found for the left Caudate Nucleus (top), for subject 1711.
The diﬀerence between the two images is given by the intermediate component,
which is so the only one connected to the activity of the tracer within the tissue
Probably the intermediate component present in the ROI blood of subjects
1711 and 1866, in corrispondence of respectively β = 0.3 and β = 0.17, is due
to the presence within the ROI of a part of tissue and not only blood. In Figure
6.6 we show the spectral lines relative to the ROI blood of subject 2241 together
with the lines of one of the 43 ROIs (Hippocampus right), with the purpose
of highlighting that only the intermediate component, in this case in position
β = 0.22, reﬂects the behaviour of the tracer within the tissue. For blood, the
low-frequency reversible component (for β = 0.02) has a higher value than the
irreversible one and its α value is detected with a good precision rather than the
α value for β = 0, which is very low and with a high degree of inaccuracy. This
is probably the reason why this subject, as we have seen in section 6.2.1, does
not present the trapping in the majority of ROIs, but present spectral lines in
corrispondence of very low beta values (0.007±0.001), that we have considered,
in ﬁrst approximation, as a shift of the irreversible component due to noise.6.2. I/O MODEL RESULTS 85
Figure 6.6: Comparison between the spectral lines of ROI blood and the ones of
right Hippocampus
That being so, the results that we have found applying the SA approach to all
the ROIs of each subject can be interpreted in this way: the irreversible process
is due to the trapping of the tracer inside the blood vessels (where we know from
physiology there is a large number of adenosine A2A receptors) and also the low
component, which is present for some subjects, as 1711 and 2241, are connected
to blood; instead the intermediate line describes the activity of the tracer within
the tissue.
These new results revealed themselves as important discoveries and they helped
us to formulate the alternative compartmental models, whose numerical results
will be present in the next sections.86 6. RESULTS
6.3 Compartmental Models
6.3.1 Traditional Models for [11C]SCH442416
We know that most quantitative PET studies of radioligand binding to neu-
roreceptor sites are analysed using models derived from the three-tissue six-rate
costant compartment model, but because of factors such as the signal to noise
ratio, condensed models with a reduced number of compartments are often used.
So ﬁrst of all we applied to our data the 4K model, which was able to describe the
kinetics of subject 2241, who did not present totally the irreversible uptake of the
tracer, instead for the others the rate costant k4 was too small to be identiﬁed,
in accordance with the SA approaches that have found a remarked trapping.
Starting from the results of the tradional SA and SAIF, to describe the irreversible
binding present in the majority of subjects we applied the 3K model which re-
vealed to be good for the patients with a low number of spectral lines, but on
the contrary it was too poor to be used for the ones with a high informative
content, i.e 1711, 2241 and 2300. In these cases, each parameter was estimated
with accuracy, but the model estimated curve was not able to describe the data,
especially in the ﬁrst part after the tracer injection, where the peak and the fol-
lowing decrease were completely understimated. To overcome this problem, we
tried to apply also the 5K model: as expected it was suitable for subjects with
slow kinetics and a large number of lines in the spectrum, instead for the oth-
ers it was too complex to describe their data, in particular the exchange of the
radioligand between the free pool and the non-speciﬁcally bound pool was rapid
so that the rate costants k5 and k6 were not estimated and we recovered the 3K
model. Using the Akaike Information Criterion we provided for each subject a
comparison between the three models, 3K, 4K and 5K, in order to ﬁnd the best
and parsimonious solution. We have that for subjects 1814, 1804 and 1866 it is
given by the 3K compartmental model, 1711 and 2300 are well described by the
5K model, lastly for 2241 the 4K model is the most suitable.
However, even if these models provide good estimates and ﬁts of the measured
data, with realistic trends of residuals, we are not able to ﬁnd a correlation be-
tween these compartmental structures and the physiological information in hand,6.3. COMPARTMENTAL MODELS 87
e.g we can not give an explanation of the irreversible trapping of the tracer. More-
over the macroparameter Vd presents a too high variability, both inter and intra
subject, which is not justiﬁable, as we can see in Figure 6.7, where we represent
the boxplot2 of these values for four subjects.
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Figure 6.7: Representation through boxplots of the macroparameter Vd: the line
inside the box is the median while the + represent the outliers. It is immediatly
clear the high variability between the subjects
So after these results and thanks to the discovery of the signiﬁcant blood
presence, we set apart these three traditional models and focused our attention
on the development of new compartmental structures.
2A boxplot is a simple way of graphically depicting groups of numerical data through their
ﬁve-number summaries: the smallest observation (minimum sample), lower quartile (Q1), me-
dian (Q2), upper quartile (Q3), and largest observation (maximum sample). It may also indicate
which observations might be considered outliers.88 6. RESULTS
6.3.2 Innovative Models for [11C]SCH442416
The problems that we noticed using the tradional models and the high amount
of blood in summed PET images lead us to the formulation of speciﬁc compart-
mental models for this tracer. In particular the results of SA applied to the ROI
blood of each subject, suggest that the tracer concentration within the tissue can
be described by a simple one-tissue compartment model, while an irreversible and
a reversible compartment are necessary to depict its activity inside blood. This
type of structure, with compartments releated to the blood presence and a com-
partment that represents the tissue, has a physiological validation, since we know
that the adenosine A2A receptors, which are the target subtype of our tracer,
are selectively expressed not only in brain areas, but also in human endothelial
cells and platelet membranes. In all the four tested compartmental models the
irreversible trapping is in the vascular part, in agreement with the spectral lines
we have found for each ROI blood, and so it represents a non-speciﬁc binding of
the tracer.
Model 1
It is the ﬁrst compartmental model that we evaluated with our PET data: it is
a parallel structure, with an irreversible and a slow reversible compartment, that
describe the vascular kinetics of the tracer, and one reversible tissue compartment,
faster than the other one. We applied this model to all six subjects; looking the
diﬀerent results (that we show in the Table 5.17-5.20) it is immediatly clear that
the “full” structure is able to describe the data of subjects 1711 and 2300; in
subject 2241 the nonspeciﬁc trapping is not detected in the majority of ROIs, as
previously found with the I/O models. Lastly for subjects 1814, 1804 and 1866
the rate costants k1 and k2 are very small and so they are not estimated by the
algorithm, therefore for these ones the reversible compartment of vascular origin
is not present, in agreement with the SA results, which in these cases does not
detect slow reversible components.
Considering the reversible tissue compartment and in particular the rate costant
k6, which describes the exchange from tissue to plasma, it can be noticed that it
assume low values in the brain areas with a large number of receptors, index that6.3. COMPARTMENTAL MODELS 89
here there is a speciﬁc binding of the tracer, instead for Cerebellum or Occipital
Lobe the tracer rapidly returns to plasma since this receptor subtype is not present
in high concentrations in these areas. As a consequence, the distribution volume
of the tracer (
K5
k6 ) within the tissue reaches the highest values in Caudate Nucleus,
Putamen, Nucleus Accumbens and Globus Pallidus, while in the other areas the
values are lower and fairly homogeneus. So this parameter is of great interest
in our study since it correlates in a good way with the physiological information
about the distribution of the A2A receptors within the brain, while the irreversible
trapping, being connected to the vascular part, does not reﬂect their characteristic
localization in tissues. In fact, the microparameter k3, which also represents the
fractional uptake K, is only a rate costant and so its value does not depend on
the number of receptors; moreover, reﬂecting the irreversible process inside blood
vessels, we don’t expect signiﬁcant changes between the diﬀerent ROIs of each
subject. We show in Figure 6.8 the values of this microparameter for three of the
four reliable subjects (2241 is not represents since the majority of ROIs don’t
present k3): we have a quite homogeneus distribution for subject 1814 while 1711
presents some regions with 0 value (in concordance with the I/O result for the
same ROIs). It is immediatly clear that this parameter is not inﬂuenced by the
number of receptors and moreover it is not correlated with the blood volume
term, i.e we don’t ﬁnd a high k3 value in regions wih a large amount of blood,
these because it only gives an idea of the velocity of trapping.
So Vd for the tissue is the macroparameter of our interesting: for each sub-
ject we sorted the values and divided them into 3 groups, with low-medium-high
values of Vd, even if between the ﬁrst two divisions there are not very remarked
diﬀerences. In this way we wanted to know if it really correlated with the ex-
pected regional A2A distribution in each subject and if there was a shared trend.
We show these divisions in Figure 6.9, where we underline the position of the in-
teresting ROIs: Cerebellum and Anterior Cingulate Gyrus are always in the ﬁrst
two groups, even if Cerebellum is not in the ﬁrst positions as expected, index
that here there is a speciﬁc binding of the tracer, and so probably can not be
considered the reference region as in the previous works. Instead the rich regions
are in practice in the last group and this is particularly evident for subject 2241,90 6. RESULTS
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Figure 6.8: Representation of k3 values for the most important ROIs. Top: 1814;
Center: 1711; Bottom: 1866
who is also the one with the higher intra variability for this parameter.
We evaluated also the ﬁt of the data, which was good for all the subjects (ex-
cept for 1804 who has probably problems in the input function), and the trends
of weighted residuals, which reﬂect the assumptions on the measurement error.
Except for some small ROIs, as Nucleus Accumbens or Globus Pallidus, the CVs
are good for all the subjects and for all the parameters, especially for k5 and Vd
(Table 6.12-15).6.3. COMPARTMENTAL MODELS 91
ROI K5[mlml−1min−1] cv k6[min−1] cv Vd [mlml−1] cv k3[min−1] cv Vb[unitless] cv
Cerebellumr 0.0382 (37) 0.9039 (36) 0.0422 (17) 0.4140 (25) 0.0287 (24)
Cerebelluml 0.0355 (29) 0.7482 (29) 0.0474 (14) 0.4229 (22) 0.0280 (21)
G cing antl 0.0283 (36) 0.6861 (36) 0.0413 (18) 0.2777 (18) 0.0436 (16)
G cing antr 0.0180 (58) 0.7175 (57) 0.0251 (30) 0.3407 (22) 0.0330 (21)
CaudateNucll 0.0346 (26) 0.5980 (27) 0.0579 (13) 0.5694 (27) 0.0213 (26)
CaudateNuclr 0.0330 (23) 0.4452 (25) 0.0741 (13) 0.5688 (31) 0.0203 (30)
NuclAccumbl 0.0146 (64) 0.3082 (72) 0.0474 (41) 0.4931 (53) 0.0243 (51)
NuclAccumbr 0.0267 (49) 0.3682 (53) 0.0724 (28) 0.4664 (52) 0.0270 (50)
Putamenl 0.0405 (16) 0.3720 (17) 0.1088 (9) 0.4425 (21) 0.0305 (20)
Putamenr 0.0402 (17) 0.3822 (18) 0.1053 (10) 0.4660 (22) 0.0302 (21)
Thalamusl 0.0382 (39) 0.9714 (38) 0.0393 (18) 0.4862 (26) 0.0268 (25)
Thalamusr 0.0290 (48) 0.7585 (48) 0.0382 (24) 0.4610 (31) 0.0266 (30)
Palliduml 0.0120 (140) 0.2408 (168) 0.0499 (100) 0.2827 (95) 0.0331 (89)
Pallidumr 0.0183 (44) 0.1353 (57) 0.1355 (37) 0.3550 (70) 0.0278 (66)
Table 6.12: Subject 1814-Model 1
ROI K5[mlml−1min−1] cv k6[min−1] cv Vd [mlml−1] cv k3[min−1] cv Vb[unitless] cv
Cerebellumr 0.0546 (15) 0.6215 (15) 0.0878 (8) 0.3020 (14) 0.0451 (13)
Cerebelluml 0.0536 (17) 0.6124 (16) 0.0875 (8) 0.2981 (15) 0.0454 (14)
G cing antl 0.0370 (20) 0.5003 (20) 0.0739 (11) 0.3239 (15) 0.0449 (14)
G cing antr 0.0385 (18) 0.4954 (17) 0.0778 (0) 0.2064 (10) 0.0660 (10)
CaudateNucll 0.0564 (8) 0.2282 (9) 0.2471 (5) 0.5200 (20) 0.0305 (20)
CaudateNuclr 0.0528 (7) 0.2515 (8) 0.2101 (4) 0.4890 (15) 0.0303 (15)
NuclAccumbl 0.0317 (28) 0.2070 (32) 0.1534 (18) 0.2446 (31) 0.0561 (29)
NuclAccumbr 0.0546 (43) 0.6292 (43) 0.0868 (22) 0.9811 (91) 0.0144 (89)
Putamenl 0.0550 (5) 0.2036 (6) 0.2699 (3) 0.3562 (10) 0.0429 (9)
Putamenr 0.0511 (7) 0.1917 (8) 0.2665 (4) 0.3861 (15) 0.0412 (14)
Thalamusl 0.0425 (16) 0.4211 (16) 0.1010 (8) 0.3489 (19) 0.0363 (18)
Thalamusr 0.0416 (19) 0.4725 (19) 0.0880 (10) 0.2905 (16) 0.0475 (15)
Palliduml 0.0152 (27) 0.1112 (38) 0.1365 (26) 0.7412 (57) 0.0159 (55)
Pallidumr 0.0368 (21) 0.1759 (26) 0.2090 (15) 0.5848 (55) 0.0236 (53)
Table 6.13: Subject 1866-Model 19
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ROI K5[mlml−1min−1] cv k6[min−1] cv Vd [mlml−1] cv k3[min−1] cv k1[min−1] cv k2[min−1] cv Vb[unitless] cv
Cerebellumr 0.0330 (2) 0.2372 (5) 0.1392 (3) - 0.1717 (12) 0.0078 (9) 0.0983 (5)
Cerebelluml 0.0356 (2) 0.2267 (6) 0.1571 (4) - 0.1669 (11) 0.0068 (8) 0.1033 (5)
G cing antl 0.0274 (5) 0.1974 (15) 0.1386 (10) - 0.1778 (26) 0.0062 (21) 0.0887 (11)
G cing antr 0.0195 (44) 0.1420 (207) 0.1375 (247) 0.0471 (157) 0.0818 (32) 0.0140 (57) 0.1331 (9)
CaudateNucll 0.0575 (13) 0.2198 (16) 0.2617 (10) - 0.1700 (23) 0.0048 (28) 0.0866 (17)
CaudateNuclr 0.0608 (11) 0.2172 (38) 0.2800 (28) - 0.2192 (45) 0.0051 (20) 0.0624 (32)
NuclAccumbl 0.0337 (30) 0.0991 (37) 0.3404 (24) 0.1056 (40) - - 0.1249 (31)
NuclAccumbr 0.0290 (26) 0.1151 (32) 0.2522 (18) 0.1068 (35) - - 0.1048 (25)
Putamenl 0.0781 (6) 0.2063 (13) 0.3787 (8) - 0.1751 (18) 0.0078 (10) 0.1031 (12)
Putamenr 0.0534 (19) 0.1937 (36) 0.2757 (48) 0.0819 (21) 0.1037 (91) 0.0429 (81) 0.1129 (13)
Thalamusl 0.0393 (4) 0.3065 (10) 0.1281 (7) - 0.1488 (27) 0.0067 (20) 0.1210 (9)
Thalamusr 0.0453 (14) 0.2444 (17) 0.1852 (10) - 0.1904 (17) 0.0049 (18) 0.0878 (14)
Palliduml 0.0530 (16) 0.1377 (17) 0.3848 (10) 0.1109 (30) - - 0.1117 (25)
Pallidumr 0.0565 (19) 0.1816 (26) 0.3113 (17) - 0.1548 (39) 0.0036 (69) 0.0947 (29)
Table 6.14: Subject 2241-Model 16
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ROI K5[mlml−1min−1] cv k6[min−1] cv Vd [mlml−1] cv k3[min−1] cv k1[min−1] cv k2[min−1] cv Vb[unitless] cv
Cerebellumr 0.0709 (5) 0.3384 (8) 0.2095 (7) 0.2015 (10) 0.2651 (11) 0.0292 (22) 0.0486 (6)
Cerebelluml 0.0712 (4) 0.3476 (7) 0.2047 (6) 0.2150 (8) 0.2889 (9) 0.0312 (17) 0.0464 (5)
G cing antl 0.0530 (9) 0.3306 (19) 0.1603 (18) 0.1462 (11) 0.3010 (19) 0.0430 (20) 0.0639 (8)
G cing antr 0.0526 (19) 0.3713 (37) 0.1417 (35) 0.1576 (17) 0.3459 (35) 0.0560 (29) 0.0637 (14)
CaudateNucll 0.0711 (11) 0.2757 (21) 0.2578 (27) 0.2919 (15) 0.6085 (40) 0.0599 (27) 0.0401 (19)
CaudateNuclr 0.0711 (6) 0.2224 (9) 0.3198 (6) - 0.6184 (18) 0.0094 (10) 0.0329 (16)
NuclAccumbl 0.0654 (20) 0.2582 (41) 0.2533 (43) 0.2688 (53) 0.5228 (58) 0.0319 (83) 0.0377 (35)
NuclAccumbr 0.0660 (19) 0.2155 (29) 0.3063 (22) - 0.4973 (50) 0.0113 (28) 0.0388 (43)
Putamenl 0.0853 (8) 0.2276 (16) 0.3747 (19) 0.2093 (18) 0.4046 (33) 0.0381 (38) 0.0492 (12)
Putamenr 0.0882 (6) 0.2129 (12) 0.4143 (13) 0.1543 (67) 0.4857 (19) 0.0207 (60) 0.0386 (15)
Thalamusl 0.0728 (6) 0.2678 (8) 0.2719 (5) - 0.3697 (11) 0.0076 (9) 0.0542 (9)
Thalamusr 0.0776 (8) 0.2986 (15) 0.2599 (12) 0.1845 (40) 0.2326 (21) 0.0203 (77) 0.0523 (13)
Palliduml 0.0485 (28) 0.1992 (48) 0.2437 (69) 0.3345 (38) 1.2681 (58) 0.0427 (44) 0.0259 (30)
Pallidumr 0.0473 (14) 0.1542 (29) 0.3066 (27) - 0.8511 (38) 0.0173 (17) 0.0316 (31)
Table 6.15: Subject 1711-Model 194 6. RESULTS
(a) Low values
(b) Medium and high values
Figure 6.9: Distribution volume values for four subjects with Model 1
Model 2
Starting from the structure of Model 1 and noting that only for some subjects
the blood reversible compartement was required, to have a full-view we tested
another possible conﬁguration with the same number of compartments and rate
costants. In this case only the irreversible process is related to blood while the
tracer activity in the tissue is described by two reversible compartments. Also for
this model the net uptake rate costant is given by k3 and it is not identiﬁable
for subject 2241, as previously, and being connected to blood it does not give us
relevant information.
The macroparameter Vd for the tissue is given by
K1
k2
 
1 +
k3
k4
 
, but for subjects
1814, 1866 and 1804 the algorithm is not able to identify the rate costants k3 and
k4 in many ROIs and so the Vd is given again by
K1
k2 . In this case this parameter
does not correlate with the physiological information, in fact we ﬁnd for some6.3. COMPARTMENTAL MODELS 95
subjects low values in corrispondence of ROIs with a large number of receptors,
e.g Nucleus Accumbens and Putamen of subject 2241, and, on the contrary,
higher values in areas like Cerebellum. In particular, this subject presents higher
Vd, 2÷3 [mlml−1], also by comparison with subject 1711, who usually has a similar
pattern. Moreover we ﬁnd a more remarked variability than the values that we
have found with Model 1, both intra (also between the left and the right part
of the same ROI) and inter subject, as we can clearly see in Figure 6.10, where
we consider only four subjects. Even if the model-estimated curves are able to
describe the data and the CV of estimates are low, this high variability, which is
not physiological, led us to reject this model conﬁguration.
Cerebellum_r Cerebellum_l
0
0.5
1
1.5
2
2.5
3
V
d
 
[
m
l
 
m
l
−
1
]
 
 
1814
1711
2241
1866
(a) ROI Cerebellum
CaudNucl_r CaudNucl_l
0
0.5
1
1.5
2
2.5
3
3.5
4
V
d
 
[
m
l
 
m
l
−
1
]
 
 
1814
1711
2241
1866
(b) ROI Caudate Nucleus
Thalamus_r Thalamus_l
0
0.5
1
1.5
2
2.5
3
3.5
4
V
d
 
[
m
l
 
m
l
−
1
]
 
 
1814
1711
2241
1866
(c) ROI Thalamus
NuclAccumb_r NuclAccumb_l
0
1
2
3
4
5
6
7
8
V
d
 
[
m
l
 
m
l
−
1
]
 
 
1814
1711
2241
1866
(d) ROI Nucleus Accumbens
Figure 6.10: Distribution volume for tissue with Model 2. Particularly evident is
the variability between subject 2241, who has high values, and the others96 6. RESULTS
Model 3 and Model 4
As previously explained, the time course of parent compound shows the presence
of a signiﬁcant amount of metabolites (diﬀerently from rats and monkeys) and
this observation suggested us to test both the I/O model with a double input
function (see Section 6.2.2) and new compartmental models accounting for their
presence. These new structures have two diﬀerent arterial input functions: the
parent plasma concentration Cp(t), i.e corrected for metabolites, and the total
plasma concentration Ctp(t), i.e with also the metabolites. The results of the
SA approach with the two inputs did not give an unique interpretation of the
behaviour of the metabolites, in particular from the interpretation of the diﬀerent
spectra of each subject we were not able to clearly distinguish if the trapping or
the low reversible component were due to the metabolites presence. For this reason
we decided to test on four of the six subjects two possible conﬁgurations, ﬁrst of
all Model 3 which has the irreversible process connected to the metabolites. We
can summerize the results that we have found as (Table 6.16-19):
- subject 1814 ⇒ the rate costant k2 is very small, ≈ 0, for all the ROIs
and the irreversible trapping is split into two parts, in fact we have k1 =
0.27 ± 0.08 and k3 = 0.07 ± 0.03, which is signiﬁcantly smaller than the
component connected to Cp(t) and it is due to metabolites; the values of
k6 are very diﬀerent from the ones of Model 1 (Model 3: k6 = 0.33 ± 0.15;
Model 1= k6 = 0.52 ± 0.27);
- subject 1711 ⇒ the full model is able to describe the data of each ROI, only
a few do not present the rate costant k3; also in this case the values of k3
are low (0.06±0.02); the values of the parameters connected to the tissue
compartment are very similar to the one that we have found with Model 1
(Model 3: K5 = 0.07 ± 0.01 k6 = 0.26 ± 0.06; Model 1: K5 = 0.07 ± 0.01
k6 = 0.27 ± 0.06);
- subject 2241 ⇒ almost all the ROIs have k3 ≈ 0, the rate costant k2 is very
low (0.008±0.007) and also in this case the tissue values are quite similar
to the same that we have found with Model 1 (Model 3: K5 = 0.05 ± 0.02
k6 = 0.18 ± 0.07; Model 1: K5 = 0.04 ± 0.02 k6 = 0.19 ± 0.06);6.3. COMPARTMENTAL MODELS 97
- subject 1866 ⇒ is very similar to 1814; k2 ≈ 0 for all the ROIs and so also
in this case the trapping is split, k1 = 0.29±0.18 k3 = 0.08±0.1; the values
of k6 are signiﬁcantly diﬀerent from the ones of Model 1.
Considering the diﬀerent numerical results, it seems that the irreversible process
requires a long time to be attuated, i.e the metabolites are slowly trapped and for
the subjects with the splitted irreversible component the one connected to Cp(t)
is more remarked. About the distribution volume Vd in the tissue, the values for
subjects 1711 and 2241 are almost equal to the ones we have calculated with
Model 1 (since K5 and k6 are the same), instead for 1814 and 1866 Vd is a bit
higher. Also in this case its values reﬂect and correlate with the adenosine A2A
receptor distribution within the brain and we report in Figure 6.11 the values
for each subject, divided as previously in three groups. Areas like Striatum and
Globus Pallidus with a large number of receptors are collocated in the last group,
and this is the index that the Vds calculated with Model 3 are correlated to the
physiological information too.
(a) Low values
(b) Medium and high values
Figure 6.11: Distribution Volume Vd with Model 39
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ROI K5[mlml−1min−1] cv k6[min−1] cv Vd[mlml−1] cv k3[min−1] cv k1[min−1] cv k2[min−1] cv Vb[unitless] cv
Cerebellumr 0.032 (12) 0.534 (13) 0.060 (7) 0.073 (13) 0.227 (13) - - 0.031 (10)
Cerebelluml 0.031 (11) 0.486 (13) 0.065 (7) 0.066 (14) 0.255 (13) - - 0.030 (10)
G cing antl 0.027 (25) 0.510 (27) 0.052 (15) 0.029 (31) 0.208 (18) - - 0.045 (13)
G cing antr 0.016 (29) 0.405 (34) 0.040 (19) 0.048 (26) 0.224 (20) - - 0.035 (15)
CaudateNucll 0.031 (15) 0.409 (18) 0.076 (10) 0.078 (27) 0.365 (22) - - 0.023 (18)
CaudateNuclr 0.032 (16) 0.341 (19) 0.094 (12) 0.078 (36) 0.377 (29) - - 0.021 (24)
NuclAccumbl 0.016 (55) 0.274 (73) 0.058 (48) 0.033 (147) 0.427 (62) - - 0.024 (52)
NuclAccumbr 0.024 (23) 0.167 (37) 0.143 (28) 0.132 (45) 0.120 (95) - - 0.031 (35)
Putamenl 0.039 (8) 0.273 (10) 0.142 (6) 0.073 (18) 0.261 (16) - - 0.032 (12)
Putamenr 0.038 (9) 0.274 (11) 0.139 (7) 0.077 (20) 0.275 (18) - - 0.032 (13)
Thalamusl 0.031 (18) 0.586 (19) 0.054 (10) 0.068 (19) 0.303 (16) - - 0.029 (13)
Thalamusr 0.023 (14) 0.358 (16) 0.065 (10) 0.097 (15) 0.211 (17) - - 0.029 (12)
Palliduml 0.017 (56) 0.129 (65) 0.132 (41) 0.138 (90) - - - - 0.031 (84)
Pallidumr 0.019 (39) 0.121 (78) 0.160 (71) 0.032 (317) 0.281 (121) - - 0.028 (68)
Table 6.16: Subject 1814-Model 36
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ROI K5[mlml−1min−1] cv k6[min−1] cv Vd[mlml−1] cv k3[min−1] cv k1[min−1] cv k2[min−1] cv Vb[unitless] cv
Cerebellumr 0.071 (4) 0.327 (7) 0.219 (6) 0.054 (13) 0.377 (9) 0.024 (17) 0.049 (6)
Cerebelluml 0.072 (4) 0.337 (6) 0.213 (5) 0.058 (10) 0.407 (7) 0.025 (13) 0.047 (5)
G cing antl 0.054 (8) 0.320 (10) 0.169 (8) 0.043 (10) 0.375 (9) 0.036 (11) 0.064 (7)
G cing antr 0.055 (17) 0.346 (31) 0.158 (28) 0.048 (18) 0.406 (26) 0.043 (22) 0.064 (14)
CaudateNucll 0.075 (8) 0.262 (16) 0.286 (18) 0.089 (16) 0.694 (26) 0.044 (19) 0.040 (13)
CaudateNuclr 0.071 (6) 0.223 (9) 0.320 (6) - 0.619 (18) 0.009 (10) 0.033 (16)
NuclAccumbl 0.066 (19) 0.260 (38) 0.256 (37) 0.078 (56) 0.691 (51) 0.029 (59) 0.037 (35)
NuclAccumbr 0.066 (22) 0.218 (37) 0.304 (35) - - 0.502 (55) 0.011 (61) 0.039 (33)
Putamenl 0.087 (6) 0.221 (13) 0.395 (15) 0.058 (23) 0.497 (23) 0.030 (30) 0.049 (12)
Putamenr 0.089 (5) 0.208 (11) 0.429 (10) 0.032 (101) 0.563 (19) 0.017 (55) 0.039 (14)
Thalamusl 0.073 (6) 0.268 (8) 0.272 (5) - 0.370 (11) 0.008 (9) 0.054 (9)
Thalamusr 0.078 (8) 0.292 (13) 0.268 (11) 0.046 (52) 0.343 (17) 0.018 (57) 0.052 (13)
Palliduml 0.051 (16) 0.195 (18) 0.260 (27) 0.098 (22) - - - - 0.026 (21)
Pallidumr 0.047 (15) 0.155 (29) 0.306 (28) - - 0.853 (38) 0.017 (17) 0.032 (31)
Table 6.17: Subject 1711-Model 31
0
0
6
.
R
E
S
U
L
T
S
ROI K5[mlml−1min−1] cv k6[min−1] cv Vd[mlml−1] cv k3[min−1] cv k1[min−1] cv k2[min−1] cv Vb[unitless] cv
Cerebellumr 0.033 (8) 0.238 (9) 0.139 (6) - - 0.172 (7) 0.008 (5) 0.098 (5)
Cerebelluml 0.036 (7) 0.227 (8) 0.157 (5) - - 0.167 (6) 0.007 (6) 0.100 (5)
G cing antl 0.027 (16) 0.197 (21) 0.139 (14) - - 0.178 (14) 0.006 (15) 0.089 (11)
G cing antr 0.021 (16) 0.129 (27) 0.160 (22) - - 0.119 (14) 0.006 (22) 0.134 (8)
CaudateNucll 0.058 (13) 0.220 (16) 0.262 (10) - - 0.170 (23) 0.005 (27) 0.087 (17)
CaudateNuclr 0.061 (16) 0.217 (19) 0.280 (12) - - 0.219 (38) 0.005 (37) 0.062 (32)
NuclAccumbl 0.040 (16) 0.066 (21) 0.609 (13) 0.031 (32) - - - - 0.130 (26)
NuclAccumbr 0.031 (14) 0.064 (18) 0.482 (11) 0.028 (25) - - - - 0.116 (20)
Putamenl 0.078 (7) 0.207 (9) 0.378 (6) - - 0.175 (16) 0.008 (13) 0.103 (12)
Putamenr 0.055 (12) 0.194 (26) 0.285 (29) 0.020 (31) 0.152 (38) 0.028 (52) 0.114 (13)
Thalamusl 0.039 (18) 0.307 (19) 0.128 (11) - - 0.149 (12) 0.007 (10) 0.121 (9)
Thalamusr 0.045 (14) 0.244 (17) 0.185 (10) - - 0.190 (17) 0.005 (18) 0.088 (14)
Palliduml 0.050 (37) 0.139 (56) 0.356 (87) 0.029 (41) 0.093 (184) 0.029 (204) 0.110 (18)
Pallidumr 0.056 (19) 0.180 (26) 0.312 (17) - - 0.154 (39) 0.004 (68) 0.095 (29)
Table 6.18: Subject 2241-Model 36
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ROI K5[mlml−1min−1] cv k6[min−1] cv Vd[mlml−1] cv k3[min−1] cv k1[min−1] cv k2[min−1] cv Vb[unitless] cv
Cerebellumr 0.048 (7) 0.456 (8) 0.106 (4) 0.047 (12) 0.176 (10) - - 0.050 (6)
Cerebelluml 0.046 (7) 0.432 (8) 0.108 (4) 0.051 (12) 0.161 (11) - - 0.051 (6)
G cing antl 0.035 (16) 0.399 (18) 0.087 (11) 0.032 (37) 0.242 (18) - - 0.048 (12)
G cing antr 0.035 (14) 0.381 (16) 0.091 (9) 0.021 (32) 0.154 (14) - - 0.070 (8)
CaudateNucll 0.056 (7) 0.212 (11) 0.265 (7) 0.037 (80) 0.430 (26) - - 0.031 (19)
CaudateNuclr 0.053 (7) 0.252 (8) 0.210 (4) - - 0.489 (16) - - 0.030 (15)
NuclAccumbl 0.032 (29) 0.208 (32) 0.153 (19) - - 0.245 (31) - - 0.056 (29)
NuclAccumbr 0.047 (42) 0.504 (47) 0.094 (25) 0.051 (206) 0.747 (87) - - 0.017 (77)
Putamenl 0.055 (4) 0.194 (7) 0.282 (5) 0.016 (91) 0.319 (15) - - 0.043 (9)
Putamenr 0.051 (5) 0.166 (9) 0.307 (7) 0.050 (41) 0.267 (22) - - 0.043 (12)
Thalamusl 0.039 (10) 0.315 (12) 0.125 (7) 0.059 (24) 0.198 (20) - - 0.040 (12)
Thalamusr 0.039 (14) 0.366 (17) 0.106 (10) 0.039 (32) 0.194 (20) - - 0.051 (12)
Palliduml 0.021 (13) 0.072 (20) 0.289 (14) 0.334 (51) - - - - 0.016 (49)
Pallidumr 0.040 (13) 0.126 (27) 0.319 (25) 0.219 (63) 0.084 (294) - - 0.025 (45)
Table 6.19: Subject 1866-Model 3102 6. RESULTS
Also in this case, the precision is good for all the subjects and in particular
the CVs relative to the macroparameter Vd are lower than the ones calculated
with Model 1.
Lastly, we decided to test on the same subjects also another structure, Model 4,
which has the same number and type of compartments of Model 3, but in this
case the irreversible process is connected to the plasma activity curve and not to
metabolites. While previously with all SA approaches and compartmental models
we have found the evident presence of an irreversible component (except for 2241),
with this model also subjects 1814 and 1866 do not present in the majority of ROIs
the trapping process (k3 = 0), in disagreement with the previous information that
showed a marked irreversible binding and so in this case the data of three of the
four subjects could be described by a reversible structure. However the values
of the rate costant k2 are very low, e.g for subject 1814 k2 = 0.009 ± 0.004 and
for 1866 k2 = 0.007 ± 0.004. For subjects 1711 and 2241 the parameters that
describe the exchanges between plasma and tissue are similar to the one found
with Model 1 (as we have seen also for Model 3) and so, consequently, also the Vd
for the tissue is nearly equal. Instead for the other two subjects the values with
Model 4 for the tissue, especially k6, are very diﬀerent, e.g for 1814 with Model
4 we have k6 = 0.3 ± 0.13 while with Model 1 k6 = 0.52 ± 0.27. On average,
the values of CVs for the parameters calculated with this model are signiﬁcantly
higher than the others found with the previous model, in fact as we can see in
the following tables (6.20-23) in some cases they are over 100 ÷200 %, especially
for subjects 1814 and 1866, while previously this happens very rarely.
Also for this compartmental model we show the Vds values, divided into the three
groups and as previously these values reﬂect the distribution of the receptors in
the brain (Figure 6.12): Cerebellum is in the ﬁrst two groups while the rich areas
are all in the last one. Moreover the ﬁts are able to explain the data in a good way,
in particular they show the same goodness of Model 3; also the weighted residuals
are consistent with the expected trends and so agree with a good estimation.6
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ROI K5[mlml−1min−1] cv k6[min−1] cv Vd[mlml−1] cv k3[min−1] cv k1[min−1] cv k2[min−1] cv Vb[unitless] cv
Cerebellumr 0.032 (10) 0.483 (11) 0.065 (6) 0 - 0.256 (9) 0.010 (6) 0.032 (8)
Cerebelluml 0.031 (10) 0.443 (6) 0.071 (6) 0 - 0.274 (10) 0.011 (6) 0.030 (8)
G cing antl 0.027 (21) 0.454 (24) 0.059 (13) 0 - 0.198 (15) 0.013 (10) 0.045 (13)
G cing antr 0.016 (667) 0.358 (4) 0.046 (668) 0 - 0.232 (16) 0.012 (12) 0.035 (48)
CaudateNucll 0.031 (14) 0.373 (17) 0.083 (10) 0 - 0.374 (19) 0.012 (11) 0.023 (17)
CaudateNuclr 0.033 (14) 0.324 (18) 0.101 (11) 0 - 0.387 (25) 0.012 (15) 0.021 (23)
NuclAccumbl 0.017 (55) 0.28 (72) 0.057 (47) 0.43 (61) 0.032 (145) - - 0.024 (52)
NuclAccumbr 0.025 (8) 0.161 (22) 0.152 (246) 0 - 0.221 (43) 0.004 (90) 0.031 (22)
Putamenl 0.039 (62) 0.258 (2) 0.152 (62) 0 - 0.282 (13) 0.011 (10) 0.032 (10)
Putamenr 0.038 (9) 0.273 (15) 0.140 (13) 0.27 (17) 0.076 (20) - - 0.032 (13)
Thalamusl 0.031 (319) 0.517 (2) 0.059 (318) 0 - 0.315 (13) 0.012 (8) 0.030 (33)
Thalamusr 0.024 (13) 0.323 (16) 0.073 (9) 0 - 0.264 (14) 0.009 (12) 0.030 (12)
Palliduml 0.017 (59) 0.128 (66) 0.132 (42) 0 - 0.138 (91) 0.000 - 0.032 (86)
Pallidumr 0.020 (320) 0.116 (105) 0.175 (394) 0.1 (100) 0.183 (110) 0.011 (516) 0.028 (68)
Table 6.20: Subject 1814-Model 41
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ROI K5[mlml−1min−1] cv k6[min−1] cv Vd[mlml−1] cv k3[min−1] cv k1[min−1] cv k2[min−1] cv Vb[unitless] cv
Cerebellumr 0.074 (4) 0.309 (7) 0.238 (6) 0.161 (11) 0.184 (12) 0.049 (17) 0.049 (6)
Cerebelluml 0.074 (3) 0.317 (6) 0.233 (5) 0.171 (9) 0.203 (10) 0.052 (14) 0.047 (5)
G cing antl 0.058 (8) 0.292 (16) 0.199 (17) 0.105 (13) 0.215 (23) 0.067 (22) 0.064 (8)
G cing antr 0.056 (18) 0.325 (35) 0.174 (40) 0.117 (17) 0.261 (50) 0.089 (39) 0.064 (14)
CaudateNucll 0.078 (12) 0.249 (20) 0.312 (28) 0.226 (15) 0.414 (58) 0.089 (41) 0.040 (14)
CaudateNuclr 0.078 (5) 0.202 (8) 0.384 (6) - - 0.340 (19) 0.024 (9) 0.033 (16)
NuclAccumbl 0.072 (16) 0.235 (35) 0.309 (37) 0.185 (69) 0.353 (62) 0.049 (73) 0.038 (34)
NuclAccumbr 0.073 (15) 0.197 (26) 0.371 (19) 0.000 - 0.271 (54) 0.027 (28) 0.039 (43)
Putamenl 0.093 (6) 0.213 (14) 0.436 (16) 0.151 (22) 0.264 (37) 0.056 (38) 0.049 (12)
Putamenr 0.095 (5) 0.200 (12) 0.476 (12) 0.084 (103) 0.316 (22) 0.036 (40) 0.039 (15)
Thalamusl 0.078 (6) 0.233 (12) 0.335 (12) 0.001 (128) 0.200 (28) 0.021 (36) 0.055 (9)
Thalamusr 0.081 (8) 0.280 (14) 0.289 (12) 0.155 (36) 0.157 (22) 0.039 (45) 0.053 (13)
Palliduml 0.062 (20) 0.173 (38) 0.360 (53) 0.166 (52) 0.784 (71) 0.060 (55) 0.026 (30)
Pallidumr 0.055 (13) 0.145 (35) 0.383 (37) - - 0.509 (54) 0.040 (32) 0.032 (33)
Table 6.21: Subject 1711-Model 46
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ROI K5[mlml−1min−1] cv k6[min−1] cv Vd[mlml−1] cv k3[min−1] cv k1[min−1] cv k2[min−1] cv Vb[unitless] cv
Cerebellumr 0.036 (8) 0.232 (12) 0.156 (8) 0 - 0.127 (10) 0.035 (5) 0.098 (6)
Cerebelluml 0.039 (5) 0.221 (9) 0.177 (6) 0 - 0.121 (8) 0.033 (5) 0.100 (5)
G cing antl 0.031 (14) 0.185 (22) 0.167 (16) 0 - 0.122 (19) 0.030 (12) 0.089 (12)
G cing antr 0.024 (15) 0.140 (31) 0.174 (29) 0 - 0.087 (21) 0.032 (17) 0.133 (8)
CaudateNucll 0.060 (12) 0.205 (16) 0.295 (10) 0 - 0.111 (26) 0.026 (15) 0.088 (17)
CaudateNuclr 0.064 (15) 0.207 (20) 0.308 (13) 0 - 0.145 (43) 0.027 (22) 0.063 (32)
NuclAccumbl 0.040 (17) 0.066 (22) 0.611 (13) 0 - 0.031 (34) 0.000 - 0.131 (27)
NuclAccumbr 0.033 (20) 0.101 (42) 0.328 (24) 0 - 0.056 (55) 0.012 (80) 0.106 (24)
Putamenl 0.081 (8) 0.200 (12) 0.406 (9) 0 - 0.124 (21) 0.034 (12) 0.104 (13)
Putamenr 0.058 (17) 0.187 (33) 0.307 (44) 0.0440 (40) 0.095 (83) 0.058 (83) 0.114 (1)
Thalamusl 0.043 (16) 0.283 (19) 0.152 (12) 0 - 0.106 (14) 0.032 (7) 0.121 (39)
Thalamusr 0.048 (12) 0.220 (17) 0.220 (11) 0 - 0.125 (19) 0.026 (11) 0.089 (13)
Palliduml 0.053 (10) 0.121 (13) 0.438 (7) 0.0740 (30) 0.000 - 0.000 - 0.116 (17)
Pallidumr 0.061 (17) 0.172 (26) 0.352 (18) 0 - 0.099 (44) 0.023 (30) 0.095 (29)
Table 6.22: Subject 2241-Model 41
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ROI K5[mlml−1min−1] cv k6[min−1] cv Vd[mlml−1] cv k3[min−1] cv k1[min−1] cv k2[min−1] cv Vb[unitless] cv
Cerebellumr 0.047 (6) 0.396 (7) 0.118 (4) 0 - 0.176 (7) 0.008 (7) 0.052 (6)
Cerebelluml 0.045 (7) 0.391 (11) 0.116 (9) 0.054 (246) 0.129 (77) 0.006 (65) 0.052 (6)
G cing antl 0.034 (13) 0.334 (15) 0.103 (9) 0 - 0.213 (12) 0.009 (11) 0.049 (11)
G cing antr 0.034 (14) 0.372 (22) 0.093 (17) 0.139 (88) 0.031 (286) 0.003 (694) 0.070 (8)
CaudateNucll 0.058 (7) 0.199 (10) 0.293 (6) 0 - 0.357 (20) 0.010 (16) 0.032 (19)
CaudateNuclr 0.054 (6) 0.232 (9) 0.235 (6) 0 - 0.371 (16) 0.012 (10) 0.031 (15)
NuclAccumbl 0.035 (30) 0.235 (41) 0.149 (28) 0 - 0.223 (37) 0.015 (27) 0.054 (31)
NuclAccumbr 0.050 (43) 0.540 (47) 0.093 (26) 0.793 (92) 0.046 (235) 0.000 - 0.016 (83)
Putamenl 0.057 (4) 0.182 (6) 0.312 (5) 0 - 0.253 (11) 0.010 (11) 0.044 (9)
Putamenr 0.053 (5) 0.157 (8) 0.338 (6) 0 - 0.243 (15) 0.008 (18) 0.043 (12)
Thalamusl 0.040 (9) 0.286 (11) 0.139 (6) 0 - 0.205 (13) 0.007 (15) 0.040 (12)
Thalamusr 0.039 (12) 0.320 (15) 0.121 (9) 0 - 0.183 (14) 0.008 (14) 0.052 (12)
Palliduml 0.021 (13) 0.073 (20) 0.288 (14) 0 - 0.334 (52) 0.000 - 0.016 (51)
Pallidumr 0.041 (14) 0.128 (24) 0.318 (18) 0 - 0.289 (55) 0.002 (189) 0.025 (47)
Table 6.23: Subject 1866-Model 46.3. COMPARTMENTAL MODELS 107
(a) Low values
(b) Medium and high values
Figure 6.12: Distribution Volume Vd with Model 4
Comparison between Model 1, Model 3 and Model 4
After having rejected Model 2, we have still three diﬀerent compartmental models
which are all able to describe our data. We can not use the Akaike Information
Criterion to choose the most parsimonious model since all the structures have
the same number of parameters. Moreover also the analysis of the diﬀerences
between the measured data and the descriptions provided by the three models
can not help our choice. Model 3 and 4 are able to describe better all the parts of
the curves, as we can see in Figure 6.13, and this is veriﬁed especially for subjects
1814 and 1866. However considering also the other subjects, the variances are not
so marked and signiﬁcant and so we can not use the ﬁt as a criterion to choose
the best model.108 6. RESULTS
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Figure 6.13: Fits and weighted residuals with the three models for subject 1814,
ROI left Putamen
First of all, we decided to compare the values of the distribution volume ob-
tained with the three models in each subject; from the observation of the previous
tables it is clear that the precisions are good for all the estimated Vds and there
are not important diﬀerences between the CVs. The values of Vds for subjects
1711 and 2241 are nearly equal through the models, while for 1814 and 1866 the6.3. COMPARTMENTAL MODELS 109
ones calculated with Model 1 are signiﬁcantly lower than the others. However, as
previously remarked, for all the three models the Vds correlate with the distribu-
tion of A2A receptors within the brain: areas as Striatum or Globus Pallidus have
always high values, as expected since they have a large number of receptors and
so the tracer can distribute itself in the tissue. Instead the Anterior Cingulate
Gyrus and Cerebellum have low Vds, even if for the last one are not so low as
expected; this is an index that here there are anyway some A2A receptors and
so the speciﬁc binding to the Cerebellum precludes its use as a reference region,
in agreement with the results of Brooks and coworkers [14]. Since there are no
evident diﬀerences between the Vds obtain with Model 1, 3 and 4 and they all
correlate with the physiological information, we can not use this macroparameter
as a criterion to choose the best one.
Lastly, we decided to compare for each subject the results of the compartmental
model with its correspondent I/O model, in fact their numerical results have to
be comparable and in agreement. We have to underline that the α and η values
of the low components for the I/O models are given by the ratio between the
estimates obtained via the nonnegative linear weighted least squares algorithm
and the blood volume Vb, i.e interpreting the values in light of the model, which
assumes that the components for β = 0 or β ≈ 0 are due to the blood presence.
The same assumption is made also for the alpha values of the traditional SA, i.e
the low components are supposed due to blood and so divided for Vb and not for
(1- Vb) as usual.
The ﬁrst consideration that appears from the observation of the results of the SA
approaches is that the I/O model with the double input function and accounting
for the metabolites presence is characterised by a high intra-subject variability,
e.g for subject 1814 there are regions like Nucleus Accumbens where all the spec-
tral lines are due to the metabolic part, and others with only one or, in same
cases, zero line connected to the Ctp(t). Moreover there is a marked inter-subject
variability, as previously seen, in fact for someone the component for β ≈ 0 is due
to metabolites (1711) while for others it is connected to parent plasma (1814)
and all these variabilities are not physiologically acceptable. Also the comparison
between the values of the parameters of Model 3 and 4 with this I/O model do110 6. RESULTS
not give the wished results (we took subjects 1814 and 1711 as samples, Figure
6.14-15). For subject 1814, with Model 3 we have an acceptable agreement be-
tween the results of the tissue part, instead the values of k3 do not correlate with
the spectral lines due to metabolites and this mismatch is also present between
k1 and the α values connected to the Cp(t). Also for subject 1711 there is a well
correlation between the values relative to the tissue part, and in this case there
is an acceptable agreement between the blood terms, even if the diﬀerences, e.g
for Putamen, between k3 and η values or the presence of 3÷4 spectral lines due
to metabolites (Cerebellum) are not physiological.
The same discrepancy is present also using Model 4, but in this case the results
are worse since this compartmental structure do not identify the irreversible trap-
ping of subjects 1814 and 1866, even if we know that this binding is present. For
1814 we have a good correlation between the results of the tissue part and the
values concerning the metabolites, but in all the ROIs k3 = 0 and so it is com-
pletely diﬀerent from the α results of SA. Also for 1711 the comparison does not
lead us to good results, in fact while the parameters of the compartmental models
correlate well with α and β values for the tissue part, the values relative to blood
are quite diﬀerent (e.g this is particularly clear for Caudate Nucleus). Moreover
for this subject the majority of the ROIs have the spectral line for β = 0 con-
nected to the metabolites presence, while Model 4 supposes the trapping to be
connected to the parent plasma.
In light of the signiﬁcant inter/intra-subject variability for the SA approach with
also metabolites and the mismatch between the results of the compartmental
models and the I/O model we decide to reject Model 3 and Model 4, because, at
present, these variations are not physiologically justiﬁable. In particular Model
4 has revealed to be worser than Model 3 for two of the four subjects, for its
low precisions of the estimates for some subjects and its inability to detect the
trapping component. Other studies are required to understand if and how the
metabolites presence should be incorporeted in the structure of the compartmen-
tal model.
Finally, we compared the results of the traditional SA technique with the param-
eters provided by Model 1. In this case the comparisons are positive, since the6.3. COMPARTMENTAL MODELS 111
α and β values well correlate with the rate costants of the model, in fact as we
can see in Figure 6.16 the values are quite similar and so there is an important
agreement between these two complementary techniques. We also present in Fig-
ure 6.17-18, for subjects 1814 and 1866 as samples, the spectral lines detected
with the traditional SA and the SA with double input function togheter with the
values of the rate costants identiﬁed with these three models. This is a further
graphical depict, it clearly shows that only Model 1 fulﬁlls the expactations, while
in the other two cases the model component are shifted or higher/lower in com-
parison with the values of the spectrum. We used one of the most important ROI
(Putamen) and particularly evident is the absence of the irreversible component
for Model 4 for this two subjects, that is one of the element that led us to reject
this model.
For this reason and also for the good precision of the estimates, for the low
diﬀerences between data and model estimated curves, for its agreement with the
physiological information we decide to propose Model 1 as the most parsimo-
nious compartmental model to describe the kinetics of [11C]SCH442416 within
the brain.112 6. RESULTS
(a) Subject 1814
(b) Subject 1711
Figure 6.14: Comparison between the numerical results of Model 3 and the I/O
model with Cp(t) and Ctp(t)6.3. COMPARTMENTAL MODELS 113
(a) Subject 1814
(b) Subject 1711
Figure 6.15: Comparison between the numerical results of Model 4 and the I/O
model with Cp(t) and Ctp(t)114 6. RESULTS
(a) Subject 1814
(b) Subject 1711
Figure 6.16: Comparison between the numerical results of Model 1 and the I/O
model with Cp(t) and Ctp(t)6.3. COMPARTMENTAL MODELS 115
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(c) Model 4
Figure 6.17: Comparison for subject 1814 between the spectral lines and the values
of the compartmental model, relative to Putamenl116 6. RESULTS
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Figure 6.18: Comparison for subject 1866 between the spectral lines and the values
of the compartmental model, relative to PutamenlChapter 7
Discussion
In the previous chapter we have presented the results found with the I/O and
compartmental models and, after the evaluation of the numerical values and of
the main characteristics of each, we decided to propose Model 1 as the best one
to describe the binding of [11C]SCH442416 to neuroreceptor sites in the brain.
In fact the traditional compartmental models normally used in this type of studies
are not able to well describe our data but in particular they are no physiologically
justiﬁable. Among the innovative structures, Model 2 presents for the macropa-
rameter Vd a too high inter/intra-subject variability which is not acceptable;
moreover we can not accept Model 3 and 4, even if they give very good ﬁts and
trends of the residuals and their Vds are correlated with the physical distribution
of the receptors in the brain areas, because, at present, their results are not in
agreement with the corrispondent I/O model. In turn, this noncompartmental
approach does not present a common trend but on the contrary we ﬁnd a marked
variability among the regions of a same subject, and this is one of the elements
that leds us to reject the compartmental models 3 and 4.
So in this chapter we wish to analyze better the results obtained with Model 1,
also to ﬁnd potential correlations between the subjects.
Distribution Volume Vd in the tissue
In Figure 6.9 we have showed the diﬀerent values found for four of the six subjects:
it is of note that the Vd values obtained by using the parameters of the tissue pool
are very low in comparison with other brain tracers, even if they are in line with
117118 7. DISCUSSION
the ones found by Brooks and coworkers, which are in the range 0.3÷0.6 [mlml−1]
(even if they consider healthy volunteers). In that ﬁgure, the values are divided
into 3 groups and it is clear that they are correlated with the localization of the
A2A receptor subtype, in particular the Anterior Cingulate Gyrus has revealed
to be particularly poor of receptors (in fact for all the subjects its Vd is in the
ﬁrst positions), while Putamen and Caudate Nucleus have conﬁrmed to be the
areas with the highest number of A2A sites. To make the division into groups, we
chose subject 2241, who presented a good range of values, and then we reported
the same thresholds also for the other subjects. However, among the Vds of the
ﬁrst two groups, especially for subjects 1814 and 1866, there is not a marked
variability and so probably we could divide all the values into only two groups,
one with low-normal values and a second with the highest values. In Figure 7.2
we show all the sorted macroparameters Vd: it is evident the low diﬀerences, for
the majority of subjects, between the ﬁrst and the second group, while in the last
part higher peaks are reached. In the x-axis we show only the increasing number
of ROIs, but we report the correspondance between the number and the speciﬁc
ROI name in the following table (Figure 7.1).
From the analysis of the numerical Vds, subject 1711 seems to have the highest
values, this is not completely true, in fact the starting point is higher in compari-
son with the other subjects (0.13 against 0.04) and so, consequently, all the values
turn out to be increased. Instead, if we make for each subject a sort of normal-
ization, i.e we divide every Vd value for the lowest one, we have more comparable
values for the macroparameter and it appears that 1711 has lower values than the
other three subjects. Moreover, it is particular evident with this normalization,
especially for 1814, 1866 and 1711, the quite equal values among the majority of
the ROIs, only from ROI number 37÷38 there is a signiﬁcant increase of the Vd,
conﬁrming that these receptors are selectively distributed and the values for the
Vd calculated with Model 1 are correlated with these information. Finally, it is a
further proof of the selectivity of [11C]SCH442416, even if the low values for this
macroparameter suggests a reduced distribution of the tracer through the BBB
within the tissue.119
Figure 7.1: Corrispondence between increasing number of x-axis and the name of
the speciﬁc ROI120 7. DISCUSSION
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Figure 7.2: Sorted Vd values for each subject, obtained with Model 1 (Vd =
K5
k6
[mlml−1])121
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Figure 7.3: Sorted Vd values after the normalization
From the physiological information, we know that only low levels of A2A re-
ceptors are present in Thalamus and in fact previous studies with other speciﬁc
tracer for this subtype have demonstrated low binding in this cerebral area: so
it is expected to have low Vd values. This consideration is followed by three sub-
jects, 1814, 2241 and 1866 (all with Parkinson’s desease and Dyskinesia), while
1711 presents values which are similar to the one found for the enriched areas
like Caudate Nucleus and Nucleus Accumbens and, anyway, higher than the Vd
calculated with Model 1 for the other three subjects. Thalamus is involved in
the process of development of involuntary movements snd so it is interesting to
understand if this result is reliable or less but, since we have only one Parkin-
son’s desease subject and no healthy control, other studies, which involve a large
number of patients, are required to ﬁnd possible correlations regarding this mo-
tor area.
A recent study by Calon and his coworkers [20], involving a larger number of
patients and another type of speciﬁc tracer for the same receptors, has demon-
strated that the A2A levels were increased in the Putamen of dyskinetic patients
compared with both controls and non-dyskinetic patients. Also the Globus Pal-
lidus revealed a higher speciﬁc binding in Parkinson’s desease subjects compared
with controls. We tried to notice if these observations were conﬁrmed also for
our tracer and patients, but since subjects 2300 (control) and 1804 (PD) were
not reliable, we could not include them in the analysis and so we had only three
dyskinetic and one no-dyskinetic patients, consequently the comparisons were122 7. DISCUSSION
very limited. Taking this reducted number into account, if we use the numerical
Vd values like so calculated with Model 1 and reported in Figure 6.9, we don’t
ﬁnd the same consideration about the Putamen with our data. In fact, if there is
a larger number of receptors in this area, a higher Vd is expected for dyskinetic
subjects, while here 1711 seems to have the highest values. However, if we use
the normalized values (as previously explained), we ﬁnd that actually dyskinetic
patients have higher values of Vd in the Putamen than the non-dyskinetic one.
Blood Parameters
In the previous chapter and in the ﬁrst part of this one, we have considered for
Model 1 the distribution volume Vd within the tissue, but it can be deﬁned also
for the vascular part. In particular, in relation to blood we have two diﬀerent
macroparameters, i.e
∗ Distribution Volume within the vasculature Vdblood =
k1
k2: it describes the
concentration of the tracer in the blood; this parameter can be deﬁned only
for the subjects who accept the reversible compartment in Model 1;
∗ Net Uptake Rate Costant K = k3: it describes the rapidity of trapping of the
tracer, present in the blood vessels, due to the receptors on the endothelial
cells or platelets.
We decided to calculate these parameters for all the four subjects, in order to
ﬁnd possible connections between the dyskinetic and no-dyskinetic patients. We
do not expect a too high intra-subject variability among the diﬀerent ROIs, since
the vasculature should be the same in all the regions and also the number of A2A
receptors, correlated to blood, should not change in relation to the particular
region (contrarily to receptors within the tissue).123
K [min−1] Vdblood [mlml−1] Vb [unitless]
1814 1711 2241 1866 1814 1711 2241 1866 1814 1711 2241 1866
ROI Cerebellumr 0.4140 0.2015 - 0.3020 - 9.0770 22.122 - 0.0287 0.0486 0.0983 0.0451
ROI Cerebelluml 0.4229 0.215 - 0.2981 - 9.2732 24.727 - 0.0280 0.0464 0.1033 0.0454
ROI G cing antl 0.277 0.1462 - 0.3239 - 7.0007 28.905 - 0.0436 0.0639 0.0887 0.0449
ROI G cing antr 0.34 0.1576 0.0471 0.2064 - 6.1803 5.8282 - 0.03 0.0637 0.1331 0.0660
ROI CaudateNucll 0.5694 0.2919 - 0.5200 - 10.155 35.7873 - 0.0213 0.0401 0.0866 0.0305
ROI CaudateNuclr 0.5688 - - 0.4890 - 65.784 42.8982 - 0.0203 0.0329 0.0624 0.0303
ROI NuclAccumbl 0.4931 0.2688 0.1056 0.2446 - 16.392 - - 0.0243 0.0377 0.1249 0.0561
ROI NuclAccumbr 0.4664 - 0.1068 0.9811 - 44.0434 - - 0.0270 0.0388 0.1048 0.0144
ROI Putamenl 0.4425 0.2093 - 0.3562 - 10.628 22.592 - 0.0305 0.0492 0.1031 0.0429
ROI Putamenr 0.4660 0.1543 0.0819 0.3861 - 23.4969 2.4181 - 0.0302 0.0386 0.1129 0.0412
ROI Thalamusl 0.4862 - - 0.3489 - 48.4495 22.368 - 0.0268 0.0542 0.121 0.0363
ROI Thalamusr 0.4610 0.1845 - 0.2905 - 11.439 38.865 - 0.0266 0.0523 0.0878 0.0475
ROI Palliduml 0.2827 0.3345 0.1109 0.7412 - 29.7331 - - 0.0331 0.0259 0.1117 0.0159
ROI Pallidumr 0.3550 - - 0.5848 - 49.1965 42.650 - 0.0278 0.0316 0.0947 0.0236
Table 7.1: Values of the blood parameters with Model 1
From the analysis of the results reported in the previous table 7.1, it appears
that 1814 and 1866, both dyskinetic patients, have a similar pattern, while 1711
and 2241, in turn, seem to have similar characteristics, even if they have a dif-
ferent diagnosis. About the blood volume Vb, as previously noticed, there is a
fairly homogeneous distribution, without signiﬁcant diﬀerences, and subject 2241
presents the higher values in comparison with the others. The distribution volume
within blood Vdblood is deﬁned only for subjects 1711 and 2241, since the others do
not present the reversible blood compartment: this macroparameter, contrarily to
the distribution volume within the tissue which is in the range [0.2÷0.4mlml−1],
reaches high values. In particular, if we consider the average, Caudate Nucleus
and Thalamus have the same results while for the other regions there are diﬀer-
ent behaviours , e.g in Nucleus Accumbens for subject 1711 we ﬁnd Vdblood = 30
while for 2241 Vdblood = 0. Moreover Vdblood is not correlated with the blood vol-
ume term: we expect that ROIs with a relative high Vb value, that indicates the
signiﬁcant presence of blood, have also a high Vdblood but this is not veriﬁed in
our subjects.
There is so a marked intra-subject variability in these ill patients, that we don’t
expect . Instead, for both patients, there is a correlation between Vdblood and K:
when k3 = 0, Vdblood is high and vice versa, in particular this is evident, also after
making the average between the two parts, for subject 2241 whose ROIs with124 7. DISCUSSION
K = 0 are Caudate Nucleus, Thalamus and Cerebellum. Instead for subjects
1711 there are marked diﬀerencies between the left and the right side and only
some parts have K = 0, e.g the right parts of Caudate Nucleus and Nucleus Ac-
cumbens. Lastly, 1814 and 1866 have for all the regions Vdblood = 0: other studies
are necessary to understand why the reversible component is not present in all
the subjects and all the ROIs.
About the parameter K, from its deﬁnition it is clear that its values don’t de-
pend on the number of receptors present in a speciﬁc ROI and in fact, as we can
see in the next ﬁgures, it is not correlated with the A2A distribution within the
brain. Subjects 1814 and 1866, as expected since they do not present the blood
distribution volume, have the highest values while the others present signiﬁcant
lower Ks, especially 2241, who does not present in many ROIs the irreversible
trapping, even if we can notice that Nucleus Accumbens has, in all the three
dyskinetic patients, high values. Finally, it appears that, except for subject 1814
and contrary to our expectations, this parameter changes in a signiﬁcant way
among the ROIs of a same subject, as it already happened for Vdblood for subjects
1711 and 2241.125
Other general considerations on Model 1
After having evaluated the micro/macro parameters relative to the tissue and
blood compartment, we ﬁnally decided to compare some concentration curves.
First of all, we considered for each subject some important ROIs, for example
Cerebellum and Putamen, and we drew the single concentrations relative to each
compartment, in order to ﬁnd possible analogies among the diﬀerent regions. We
tried to draw the single concentrations without the correction term, but in this
case the one relative to the irreversible trapping became overriding (arriving to
200÷300 [
kBq
ml ]) and covered the others: so we multiplied the values of concen-
tration for Vb, if they were relative to the blood compartment, or for 1 − Vb, if
they were refered to tissue. From the observation of the results, the concentration
values relative to the tissue compartment (which is the most important one for
our studies, since it represents the speciﬁc binding) conﬁrm the previous result
in regard to the ability of this model to correlate with the physiological informa-
tion about the distribution of the receptors within the brain. In fact Putamen
and Caudate Nucleus present higher values than Cerebellum or Anterior Cingu-
late Gyrus, and in particular for these regions the curves present a more rapid
course, index of the low amount of binding sites. Moreover, the values found for
the dyskinetic patients are lower than the ones of the unique non-dyskinetic sub-
ject 1711: other Parkinson’s desease subjects are required to check on this result,
since for Putamen we expect an opposite conclusion. About the blood reversible
compartment, if present, we can notice that it is a predominant component for
subject 2241, who presents higher values, an elevate area under the curve (AUC)
and a slower decrease in comparison with 1711. Inside the same subject, Putamen
and Cerebellum do not change signiﬁcantly, as expected from the values of their
relative Vdblood. Finally, the concentration curves relative to the irreversible com-
partment are similar among the three subjects who present the trapping process
and they assume high values, as we can see in Figure 7.4, index that the non-
speciﬁc binding inside the blood vessels is signiﬁcant for this tracer. It appears
clearly from the observation of this ﬁgure that the information obtained with this
tracer is vascular and not relative to tissue, and this can be considered a negative
characteristic of the tracer.126 7. DISCUSSION
Figure 7.4: Concentration curves relative to two ROIs, Putamenl and Cerebelluml,
considering separately each compartment127
For each subject, we also evaluated the striatum to cerebellum radioactivity
concentration ratios, since, in previous studies [10], it was used as an index of in
vivo binding of the tracer to A2A receptors. As already seen in Chapter 3, studies
on rats have found that at the time of the maximum uptake (between 5 and 15
mins after the injection) the ratio was 4.6 while the PET experiment on monkeys
brain showed values two times lower than those measured in rats (the maximum
value was 2.2). However they expected a higher ratio for the in vivo measurament
in human brain, but in our analysis this expectation is not respected. In fact, using
the single concentration curves relative to the tissue compartment, we calculated
this ratio and we found that it was 2.2÷2.6 (between 10 and 15 mins after the
tracer injection) for subjects 1814, 1711 and 2241, in line with the results on
monkeys, only for 1866 it was 4.5. So these results, even if the number of subjects
is limited and for one of the them the value is signiﬁcantly diﬀerent, suggest
that this tracer also in human subjects presents a good kinetic proﬁle but a low
striatum to cerebellum ratios and this could be problematic for its use.
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Figure 7.5: Striatum to Cerebellum ratiosChapter 8
Conclusions
[11C]SCH442416 is a PET tracer that is speciﬁc for the adenosine A2A receptors,
which are only locally expressed within the brain, and gave good results in the
preclinical studies on rats and monkeys. To investigate its characteristics, distri-
bution and activity we included in our work the data of six subjects (3 dyskinetic
Parkinson’s disease subjects, 2 Parkinson’s disease subjects and 1 healthy con-
trol), even if, after a ﬁrst qualitative analysis, we discovered that two of them
(the healthy volunteer and one non-dyskinetic patients) had problems during the
execution of the study and so their data were not reliable and useful to make the
diﬀerent comparisons.
We performed the analysis of the tracer at region of interest level and, to extract
the useful information from the data, diﬀerent approaches were used. An input-
output technique, usually refered to as Spectral Analysis, was ﬁrst used, both
to quantify some variables of interest and, especially, to deﬁne the most appro-
priate compartment model to describe our set of data. In fact, starting from the
interpretation of the obtained spectrum, this approach is suitable to ﬁnd the min-
imum number of compartments needed to explain the kinetics of the tracer in the
brain, even if it can not say anything about their connections. The traditional SA
approach gives on our data good results and, despite some diﬀerent behaviours
among the subjects, it detects the reversible components and the presence of a
signiﬁcant irreversible process within the system. Also the ﬁt and the precision
of the variables of interest are good, even if the use of a discrete ﬁxed beta grid
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and the presence of noise create some problems, like the phantom components,
the double lines close to the real value, the shift of the irreversible line (i.e the
one for β = 0) and a split spectrum.
To overcome some of these problems, e.g the great number of intermediate com-
ponents for some subjects, we decided to apply a new SA technique, called SAIF:
it uses prior information concerning irreversibility of trapping of the tracer as well
as components that cannot be distinguished from blood (in fact, the values for
β → ∞ or very close are considered vascular components and they are reasumed
in the blood volume term V b). This information determinates the value of a cut-
oﬀ interval that the SAIF uses to select the range of the equilibrating components
distinguishable in the data to be analyzed. This method applied to our dataset
gives as previously good results and ﬁts, and in this case the number of detected
components is reduced, since it is able to eliminate the problem of double lines.
Moreover the precisions of the α values, and not only of the estimated macropa-
rameters, are good (while with the traditional SA they were detected with very
low precisions). Following the guidelines dictated by the SA approach, we tried to
deﬁne the most suitable compartmental model, in order to describe the kinetics
of our PET tracer data: the traditional models present in literature, as 3K or 5K
model, were not suitable in our case and in particular they had not a physiolog-
ical explanation. After the discovery, on summed PET images, of large vascular
areas and of a large amount of rapid metabolites, we decided to propose some
innovative compartmental structures for this tracer. In particular we focused our
attention on three models (Model 1, Model 3 and Model 4), two of whom with
a double arterial plasma input function, and through the comparison of their re-
sults we tried to choose the best one. Even if Models 3 and 4 provided good ﬁts of
the data and their distribution volume macroparameter was correlated with the
physiological information about the selective distribution of A2A sites within the
brain, we decided to reject them, because of their high intra-subject variability
and the marked disagreement between the results of these compartmental struc-
tures and their correspondent I/O model. Moreover, for Model 3 the irreversible
process due to the metabolites seemed to be very slow, while Model 4 was not
able to estimate the trapping for some subjects, even if the traditional SA on the131
same ones detected a marked irreversible component. Other studies are required
to understand how it is possible to formulate new compartmental models for this
tracer taking into account the metabolites presence.
Instead Model 1 presented a precise concordance with the results of SA, as well
as the previous characteristics quoted for the other two models, even if, in this
case, for some subjects the model estimated curves under/overstimated the data
in some parts. Moreover this structure is in agreement with a previous model
present in literature to describe the kinetics of [11C]SCH442416 and proposed by
Brooks and coworkers, in fact their compartmental model presents a fast, speciﬁc,
reversible compartment and a slow, irreversible, non-speciﬁc one. Even if we have
for some subjects the presence of another reversible compartment, also in our
structure we suppose that the trapping is relative to blood and so it represents a
non-speciﬁc binding of the tracer. So despite the low number of subjects that we
involved in our study, the results and the performance of the various techniques
that we applied lead us to propose Model 1 as the most parsimonious compart-
mental model to describe the kinetics of the tracer in brain areas.
Further studies, involving a large number of dyskinetic, non-dyskinetic and healthy
patients, are required to conﬁrm the reliability of this model, to investigate the
role of the second reversible blood compartment present for some subjects and
to ﬁnd possible correlations between the diﬀerent pathologies of these subjects.
Finally, they are also necessary to demonstrate the eﬀective potentialities of
[11C]SCH442416 for the invivo imaging of A2A receptors and to analyze if it
is possible to use adenosine receptor antagonists, like this one, as new powerful
treatments for Parkinson’s disease.Appendix A
While the traditional compartmental models, like the 3K, 4K and 5K models,
have been at lenght investigated [21], Model 1 is a new and innovative structure:
in this section we will derive its equations and study its identiﬁability.
To derive Model 1 in terms of concentration, we start by formulating the model
in terms of mass: the mass representation is shown in Figure 8.1.
Figure 8.1: Model 1 in term of mass, qp,q1,q2,q3
The mass balance equations are
dq1(t)
dt
= K1qp(t) − k2q1(t) q1(0) = 0
dq2(t)
dt
= K3qp(t) q2(0) = 0
dq3(t)
dt
= k5qp(t) − k6q3(t) q3(0) = 0
(8.1)
where qp,q1 and q2 represent the amount of tracer in plasma and blood space,
while q3 is the amount in tissue. Deﬁning q(t) = C(t)V and supposing that the
plasma concentration has a Vp volume, that the two compartments relative to
blood have a Vblood volume and the tissue compartment has a generic VT volume,
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the system 8.1 can be written as:
dC1(t)
dt
  Vblood = K1Cp(t)Vp − k2C1(t)Vblood VbloodC1(0) = 0
dC2(t)
dt
  Vblood = K3Cp(t)Vp VbloodC2(0) = 0
dC3(t)
dt
  VT = k5Cp(t)Vp − k6C3(t)VT VTC3(0) = 0
(8.2)
Remembering that
Vblood = Vp + VRC
H =
VRC
Vblood
(8.3)
where H is the haematocrit, i.e the proportion of blood volume occupied by red
blood cells, we have that Vp = (1 − H)Vblood. Dividing the equations 8.2 for the
volume term, the new system is:
dC1(t)
dt
= K1(1 − H)Cp(t) − k2C1(t)
dC2(t)
dt
= K3(1 − H)Cp(t)
dC3(t)
dt
= k5Cp(t)
Vp
VT
− k6C3(t)
(8.4)
Deﬁning K5 = k5
Vp
VT , which is the reason why K5 as a diﬀerent unit of measure-
ment,
mlplasma
mltissue   min−1, and including the (1-H) term inside the rate costants k1
and k3, we ﬁnally obtain the equation 5.24 of Chapter 5, i.e:
dC1(t)
dt
= k1Cp(t) − k2C1(t) C1(0) = 0
dC2(t)
dt
= k3Cp(t) C2(0) = 0
dC3(t)
dt
= K5Cp(t) − k6C3(t) C3(0) = 0
(8.5)
The total amount measured by PET, q(t), is the summation of the amounts
present in the vascular and tissue part of the ROI, i.e q(t) = q1(t)+q2(t)+q3(t)+
qp(t) and expressing this equation in terms of concentrations we have:
C(t)VTOT = C1(t)Vblood + C2(t)Vblood + C3(t)VT + Cb(t)Vblood (8.6)135
Remembering that
VTOT = Vblood + VT
Vb =
Vblood
VTOT
(8.7)
the equation 8.6, after the division for the term VTOT, can be written as:
C(t) = C1(t)Vb + C2(t)Vb + C3(t)  
VT
VTOT
+ Cb(t)Vb
= [C1(t) + C2(t)]Vb + C3(t)  
VTOT − Vbloood
VTOT
+ Cb(t)Vb
= [C1(t) + C2(t)]Vb + C3(t)(1 − Vb) + Cb(t)Vb
(8.8)
The system of equations 8.5, which describes Model 1, is a priori uniquely iden-
tiﬁable, if it is deﬁned in this way and with the parameterization relative to the
parameter k5. We use the transfer function method to analyze the idenﬁability of
this model: taking Laplace transforms of Equations 8.5 and rearranging them we
have
sC1(s) = k1Cp(s) − k2C1(s)
sC2(s) = k3Cp(s)
sC3(s) = K5Cp(s) − k6C3(s)
(8.9)
Solving for C1, C2 and C3
C1(s) =
k1
s + k2
Cp(s)
C2(s) =
k3
s
Cp(s)
C3(s) =
K5
s + k6
Cp(s)
(8.10)
So, the Laplace transform of the total concentration C(t) can be written as:
C(s) =
s2(k1Vb + k3Vb + K5 − K5Vb) + s(k1k6Vb + k2k3Vb + k3k6Vb + k2K5 − k2K5Vb)
s3 + s2(k2 + k6) + s(k2k6)
+
k2k6k3Vb
s3 + s2(k2 + k6) + s(k2k6)
  Cp(s) + VbCb(s)
(8.11)136 8. CONCLUSIONS
The exhaustive summary of the model is:
φ1 = (k1 + k3 − K5)Vb + K5
φ2 = (k1k6 + k3k2 + k3k6 − k2K5)Vb + k2K5
φ3 = k2k6k3Vb
φ4 = k2 + k6
φ5 = k2k6
φ6 = Vb
(8.12)
where φ1,    ,φ6 are the known observational parameters: the model is identiﬁ-
able since it is possible to solve for all the six unknown parameters of the model.Bibliography
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